

04-03-00

03/31/00
JC712US. PTO

REV. 12/99
For Other Than A Small Entity

JC553 U.S. PTO
09/540466
03/31/00
A
for sequ

Docket No. STK-6

Applicant(s) : Ugo Ripamonti, et al.
For : METHODS FOR INDUCING ANGIOGENESIS USING
MORPHOGENIC PROTEINS AND STIMULATORY
FACTORS

EXPRESS MAIL CERTIFICATION

"Express Mail" mailing label number EI187447715US.

Date of Deposit March 31, 2000.

I hereby certify that this transmittal letter and the other papers and fees identified in this transmittal letter as being transmitted herewith are being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 C.F.R. § 1.10 on the date indicated above and are addressed to the Hon. Assistant Commissioner for Patents, Washington, D.C. 20231.

Michael C. Secondo
MICHAEL C SECONDO

Hon. Assistant Commissioner
for Patents
Washington, D.C. 20231
New York, New York
March 31, 2000

TRANSMITTAL LETTER FOR
ORIGINAL PATENT APPLICATION

Sir:

Transmitted herewith for filing are the
[X] specification; [X] claims; [X] abstract; [X] declaration
and [X] power of attorney, for the above-identified patent
application; [X] sequence listing (paper copy and computer
readable form); [X] Statement To Support Filing And
Submission In Accordance With 37 C.F.R. §§ 1.821-1.825.

Also transmitted herewith are:

[X] 10 sheets of:

[] Formal drawings.

[X] Informal drawings. Formal drawings will be filed
during the pendency of this application.

[] Certified copy(ies) of application(s)

(country)	(appln. no.)	(filed)
-----------	--------------	---------

(country)	(appln. no.)	(filed)
-----------	--------------	---------

(country)	(appln. no.)	(filed)
-----------	--------------	---------

from which priority is claimed.

[] An assignment of the invention to _____
_____.

[] A check in the amount of \$40.00 to cover the recording fee.

[] Please charge \$40.00 to Deposit Account No. 06-1075 in payment of the recording fee. A duplicate copy of this transmittal letter is transmitted herewith.


[] An associate power of attorney.

The filing fee has been calculated as shown below:

FOR	NUMBER FILED	NUMBER EXTRA	RATE	FEE
BASIC FEE				\$690.00
TOTAL CLAIMS	60 - 20 =	40	X \$ 18 =	\$720.00
INDEPENDENT CLAIMS	2 - 3 =	0	X \$ 78 =	\$
[X] MULTIPLE DEPENDENT CLAIMS			+ \$260 =	\$260.00
			TOTAL	<u>\$1670.00</u>

00446 990450

- [X] A check in the amount of \$1670.00 in payment of the filing fee is transmitted herewith.
- [] This application is being filed unaccompanied by a filing fee. The appropriate filing fee will be paid in response to a Notice to File Missing Parts, pursuant to 37 C.F.R. § 1.53(f).
- [X] The Commissioner is hereby authorized to charge payment of any additional filing fees required under 37 C.F.R. § 1.16, in connection with the paper(s) transmitted herewith, or credit any overpayment of same, to deposit Account No. 06-1075. A duplicate copy of this transmittal letter is transmitted herewith.
- [] Amend the specification by inserting before the first line the sentence: -- This is a [] continuation-in-part, of application Serial No.: _____, filed _____, entitled _____.
- [] Please charge \$_____ to Deposit Account No. 06-1075 in payment of the filing fee. A duplicate copy of this transmittal letter is transmitted herewith.



James F. Haley, Jr. (Reg. No. 27,794)
Attorney for Applicants
Karen Mangasarian (Reg. No. 43,772)
Agent for Applicants
FISH & NEAVE
Customer No. 1473
1251 Avenue of the Americas
New York, New York 10020-1104
Tel.: (212) 596-9000

Variable	Mean	SD	Min	Max
Age	22.2	2.1	18	28
Gender	0.5	0.5	0	1
Marital status	0.1	0.3	0	1
Education	12.5	1.5	10	16
Income	1.2	0.8	0.5	2.5
Health status	1.5	0.5	1	2
Stress level	2.5	1.0	1	4
Life satisfaction	3.5	1.0	1	5
Work satisfaction	3.0	1.0	1	5
Family satisfaction	3.5	1.0	1	5
Community satisfaction	3.0	1.0	1	5
Overall satisfaction	3.2	1.0	1	5

1990

Variable	Mean	SD	Min	Max
Age	22.2	2.1	18	28
Gender	0.5	0.5	0	1
Marital status	0.1	0.3	0	1
Education	12.5	1.5	10	16
Income	1.2	0.8	0.5	2.5
Health status	1.5	0.5	1	2
Stress level	2.5	1.0	1	4
Life satisfaction	3.5	1.0	1	5
Work satisfaction	3.0	1.0	1	5
Family satisfaction	3.5	1.0	1	5
Community satisfaction	3.0	1.0	1	5
Overall satisfaction	3.2	1.0	1	5

Variable	Mean	SD	Min	Max
Age	22.2	2.1	18	28
Gender	0.5	0.5	0	1
Marital status	0.1	0.3	0	1
Education	12.5	1.5	10	16
Income	1.2	0.8	0.5	2.5
Health status	1.5	0.5	1	2
Stress level	2.5	1.0	1	4
Life satisfaction	3.5	1.0	1	5
Work satisfaction	3.0	1.0	1	5
Family satisfaction	3.5	1.0	1	5
Community satisfaction	3.0	1.0	1	5
Overall satisfaction	3.2	1.0	1	5

Variable	Mean	SD	Min	Max
Age	22.2	2.1	18	28
Gender	0.5	0.5	0	1
Marital status	0.1	0.3	0	1
Education	12.5	1.5	10	16
Income	1.2	0.8	0.5	2.5
Health status	1.5	0.5	1	2
Stress level	2.5	1.0	1	4
Life satisfaction	3.5	1.0	1	5
Work satisfaction	3.0	1.0	1	5
Family satisfaction	3.5	1.0	1	5
Community satisfaction	3.0	1.0	1	5
Overall satisfaction	3.2	1.0	1	5

Variable	Mean	SD	Min	Max
Age	22.2	2.1	18	28
Gender	0.5	0.5	0	1
Marital status	0.1	0.3	0	1
Education	12.5	1.5	10	16
Income	1.2	0.8	0.5	2.5
Health status	1.5	0.5	1	2
Stress level	2.5	1.0	1	4
Life satisfaction	3.5	1.0	1	5
Work satisfaction	3.0	1.0	1	5
Family satisfaction	3.5	1.0	1	5
Community satisfaction	3.0	1.0	1	5
Overall satisfaction	3.2	1.0	1	5

Variable	Mean	SD	Min	Max
Age	22.2	2.1	18	28
Gender	0.5	0.5	0	1
Marital status	0.1	0.3	0	1
Education	12.5	1.5	10	16
Income	1.2	0.8	0.5	2.5
Health status	1.5	0.5	1	2
Stress level	2.5	1.0	1	4
Life satisfaction	3.5	1.0	1	5
Work satisfaction	3.0	1.0	1	5
Family satisfaction	3.5	1.0	1	5
Community satisfaction	3.0	1.0	1	5
Overall satisfaction	3.2	1.0	1	5

Variable	Mean	SD	Min	Max
Age	22.2	2.1	18	28
Gender	0.5	0.5	0	1
Marital status	0.1	0.3	0	1
Education	12.5	1.5	10	16
Income	1.2	0.8	0.5	2.5
Health status	1.5	0.5	1	2
Stress level	2.5	1.0	1	4
Life satisfaction	3.5	1.0	1	5
Work satisfaction	3.0	1.0	1	5
Family satisfaction	3.5	1.0	1	5
Community satisfaction	3.0	1.0	1	5
Overall satisfaction	3.2	1.0	1	5

Variable	Mean	SD	Min	Max
Age	22.2	2.1	18	28
Gender	0.5	0.5	0	1
Marital status	0.1	0.3	0	1
Education	12.5	1.5	10	16
Income	1.2	0.8	0.5	2.5
Health status	1.5	0.5	1	2
Stress level	2.5	1.0	1	4
Life satisfaction	3.5	1.0	1	5
Work satisfaction	3.0	1.0	1	5
Family satisfaction	3.5	1.0	1	5
Community satisfaction	3.0	1.0	1	5
Overall satisfaction	3.2	1.0	1	5

Methods For Inducing Angiogenesis Using Morphogenic
Proteins and Stimulatory Factors

BACKGROUND OF THE INVENTION

Hemovascular development is a process that
5 involves vasculogenesis, the *de novo* formation of blood
vessels through the aggregation of endothelial cells
derived from mesenchyme, and angiogenesis, the growth
of new blood vessels from a pre-existing vascular
network (Zimrin and Maciag, J. Clin. Invest., 97, p.
10 1395 (1996); Yancopoulos et al., Cell, 93, pp. 661-664
(1998); Isner and Asahara, J. Clin. Invest., 103,
pp.1231-1236 (1999)). Vasculogenesis is normally
involved in embryonic development whereas angiogenesis,
which also plays a role in the development of the
15 embryo, is of central importance in various
physiological and pathological processes in the adult
(Folkman, Ann. N.Y. Acad. Sci., 401, pp. 212-227
(1982); Folkman and Klagsbrun, Science, 235, pp. 442-
447 (1987); Bussolino et al., Trends Biochem. Sci., 22,
20 pp. 251-256 (1997); Glowacki, Clin. Orthop., 355, pp.
S82-S89 (1998); Gerber et al., Nat. Med., 5, pp.623-628
(1999)).

Various physiological processes and
15 pathophysiologies require angiogenesis. These include
reproduction, wound healing, organ transplantation,
bone repair, ischemic heart disease and ischemic
peripheral vascular disease.

Similarly, angiogenesis plays a role in organ
25 transplantation. Vascularization is essential for the
functioning of a newly transplanted organ.

30 Angiogenesis also plays a vital role during
tissue formation. In order for a specific tissue to
form, there is a need for proper vascular invasion of

repair. This superfamily includes osteogenic proteins ("OPs") and bone morphogenic proteins ("BMPs"). OPs and BMPs share a highly conserved, bioactive cysteine-rich domain near their C-termini and have a propensity to form homo- and hetero-dimers.

Many morphogenic proteins belonging to the BMP family have been described. Some were isolated using purification techniques on the basis of osteogenic activity. Others were identified and cloned by virtue of DNA sequence homologies within conserved regions that are common to the BMP family. These homologs are referred to as consecutively numbered BMPs whether or not they have demonstrable osteogenic activity. While several of the earliest members of the BMP family were identified by virtue of their ability to induce new cartilage and bone, a number of other BMPs have different or additional tissue-inductive capabilities. Other BMPs have been reported to induce other tissues. For example, a BMP-like member of the TGF- β superfamily, GDF-5 reportedly has some angiogenic activity. BMP-2, which is a member of the TGF- β superfamily family, however, does not (Yamashita et al., Exp. Cell. Res., 235, pp. 218-226 (1997)). In addition, BMP-12 and BMP-13 (identified by DNA sequence homology) reportedly induce tendon/ligament-like tissue formation *in vivo* (WO 95/16035). Several BMPs, including some of those originally isolated on the basis of their osteogenic activity, can induce neuron proliferation and promote axon regeneration (WO 95/05846; Liem et al., Cell, 82, pp. 969-79 (1995)). Thus, it appears that BMPs may have a variety of potential tissue-inductive capabilities whose final

0954046.033100
007EE0" 99404560

expression depends on a complex set of developmental and environmental cues.

The availability of large amounts of purified and highly active morphogenic proteins would
5 revolutionize procedures generally involving vascular tissue regeneration. Many of the mammalian OP- and BMP-encoding genes are now cloned and may be recombinantly expressed as active homo- and heterodimeric proteins in a variety of host systems,
10 including bacteria. The ability to recombinantly produce active forms of morphogenic proteins such as OPs and BMPs, including variants and mutants with increased bioactivities (see below), make potential therapeutic treatments using morphogenic proteins
15 feasible.

Given the potential therapeutic uses for morphogenic proteins in inducing angiogenesis, there is a need for highly active forms of morphogenic proteins. It would thus be desirable to increase the angiogenic
20 properties of morphogenic proteins. With increased angiogenic activity, treatment with a morphogenic protein, could induce angiogenesis more rapidly, or angiogenic induction could be achieved using reduced morphogenic protein concentrations.

25 SUMMARY OF THE INVENTION

This invention is based on the discovery that morphogenic proteins possess angiogenic activity and that the angiogenic inductive ability of a morphogenic protein can be enhanced by a morphogenic protein
30 stimulatory factor (MPSF).

Accordingly, this invention features a method for inducing angiogenesis at a target locus in a mammal

034046.0340

using morphogenic proteins. In addition, this invention also features a method for improving the angiogenic capability of a morphogenic protein at a target locus in a mammal. In this method, the

5 morphogenic protein is capable of inducing angiogenesis when accessible to a progenitor cell in the mammal, and the morphogenic protein stimulatory factor enhances that capability. The morphogenic protein and MPSF can be administered simultaneously to the target locus.

10 Alternatively, the two components are administered separately, in any order.

The morphogenic protein may comprise a pair of subunits disulfide-bonded to produce a dimeric species, wherein at least one of the subunits comprises

15 a polypeptide belonging to the BMP protein family. For instance, the morphogenic protein may comprise an amino acid sequence sufficiently duplicative of the amino acid sequence of a reference BMP such as BMP-2, BMP-3, BMP-4, BMP-5, BMP-6, BMP-7 (OP-1), BMP-8, BMP-9, BMP-

20 10, BMP-11, BMP-12, BMP-13, BMP-14, BMP-15, COP-5, COP-7, such that it has morphogenic activity similar to that of the reference BMP. In one preferred embodiment, the morphogenic protein is a homo- or heterodimer comprising a BMP-7 (OP-1) subunit.

25 Alternatively, the morphogenic protein may comprise a monomeric species. However, when the morphogenic protein is used in the absence of a morphogenic protein stimulatory factor, the morphogenic protein may not be BMP-2 or GDF-5.

30 The morphogenic protein used in the method of this invention is capable of inducing angiogenesis. For instance, it may be capable of inducing a

Table 1. Demographic characteristics of the study population	
Characteristic	Frequency (%)
Age (years)	
< 18	10 (10.0)
18-24	20 (20.0)
25-34	30 (30.0)
35-44	20 (20.0)
45-54	10 (10.0)
55-64	10 (10.0)
65-74	10 (10.0)
75-84	10 (10.0)
85-94	10 (10.0)
≥ 95	10 (10.0)
Gender	
Male	50 (50.0)
Female	50 (50.0)
Ethnicity	
White	30 (30.0)
Black	20 (20.0)
Hispanic	10 (10.0)
Asian	10 (10.0)
Other	10 (10.0)
Marital status	
Married	30 (30.0)
Single	20 (20.0)
Divorced	10 (10.0)
Widowed	10 (10.0)
Never married	10 (10.0)
Education level	
High school or less	20 (20.0)
Some college	10 (10.0)
Bachelor's degree	10 (10.0)
Master's degree	10 (10.0)
Doctorate degree	10 (10.0)
Other	10 (10.0)
Occupation	
Unemployed	10 (10.0)
Retired	10 (10.0)
Other	10 (10.0)
Health insurance	
Medicare	10 (10.0)
Medicaid	10 (10.0)
Private	10 (10.0)
Other	10 (10.0)
Other	10 (10.0)

Table 1. Demographic characteristics of the study population	
Characteristic	Frequency (%)
Age (years)	
< 18	10 (10.0)
18-24	20 (20.0)
25-34	30 (30.0)
35-44	20 (20.0)
45-54	10 (10.0)
55-64	10 (10.0)
65-74	10 (10.0)
75-84	10 (10.0)
85-94	10 (10.0)
≥ 95	10 (10.0)
Gender	
Male	50 (50.0)
Female	50 (50.0)
Ethnicity	
White	30 (30.0)
Black	20 (20.0)
Hispanic	10 (10.0)
Asian	10 (10.0)
Other	10 (10.0)
Marital status	
Married	30 (30.0)
Single	20 (20.0)
Divorced	10 (10.0)
Widowed	10 (10.0)
Never married	10 (10.0)
Education level	
High school or less	20 (20.0)
Some college	10 (10.0)
Bachelor's degree	10 (10.0)
Master's degree	10 (10.0)
Doctorate degree	10 (10.0)
Other	10 (10.0)
Occupation	
Unemployed	10 (10.0)
Retired	10 (10.0)
Other	10 (10.0)
Health insurance	
Medicare	10 (10.0)
Medicaid	10 (10.0)
Private	10 (10.0)
Other	10 (10.0)
Other	10 (10.0)

Table 1. Demographic characteristics of the study population	
Characteristic	Frequency (%)
Age (years)	
< 18	10 (10.0)
18-24	20 (20.0)
25-34	30 (30.0)
35-44	20 (20.0)
45-54	10 (10.0)
55-64	10 (10.0)
65-74	10 (10.0)
75-84	10 (10.0)
85-94	10 (10.0)
≥ 95	10 (10.0)
Gender	
Male	50 (50.0)
Female	50 (50.0)
Ethnicity	
White	30 (30.0)
Black	20 (20.0)
Hispanic	10 (10.0)
Asian	10 (10.0)
Other	10 (10.0)
Marital status	
Married	30 (30.0)
Single	20 (20.0)
Divorced	10 (10.0)
Widowed	10 (10.0)
Never married	10 (10.0)
Education level	
High school or less	20 (20.0)
Some college	10 (10.0)
Bachelor's degree	10 (10.0)
Master's degree	10 (10.0)
Doctorate degree	10 (10.0)
Other	10 (10.0)
Occupation	
Unemployed	10 (10.0)
Retired	10 (10.0)
Other	10 (10.0)
Health insurance	
Medicare	10 (10.0)
Medicaid	10 (10.0)
Private	10 (10.0)
Other	10 (10.0)
Other	10 (10.0)

Table 1. Demographic characteristics of the study population	
Characteristic	Frequency (%)
Age (years)	
< 18	10 (10.0)
18-24	20 (20.0)
25-34	30 (30.0)
35-44	20 (20.0)
45-54	10 (10.0)
55-64	10 (10.0)
65-74	10 (10.0)
75-84	10 (10.0)
85-94	10 (10.0)
≥ 95	10 (10.0)
Gender	
Male	50 (50.0)
Female	50 (50.0)
Ethnicity	
White	30 (30.0)
Black	20 (20.0)
Hispanic	10 (10.0)
Asian	10 (10.0)
Other	10 (10.0)
Marital status	
Married	30 (30.0)
Single	20 (20.0)
Divorced	10 (10.0)
Widowed	10 (10.0)
Never married	10 (10.0)
Education level	
High school or less	20 (20.0)
Some college	10 (10.0)
Bachelor's degree	10 (10.0)
Master's degree	10 (10.0)
Doctorate degree	10 (10.0)
Other	10 (10.0)
Occupation	
Unemployed	10 (10.0)
Retired	10 (10.0)
Other	10 (10.0)
Health insurance	
Medicare	10 (10.0)
Medicaid	10 (10.0)
Private	10 (10.0)
Other	10 (10.0)
Other	10 (10.0)

Table 1. Demographic characteristics of the study population	
Characteristic	Frequency (%)
Age (years)	
< 18	10 (10.0)
18-24	20 (20.0)
25-34	30 (30.0)
35-44	20 (20.0)
45-54	10 (10.0)
55-64	10 (10.0)
65-74	10 (10.0)
75-84	10 (10.0)
85-94	10 (10.0)
≥ 95	10 (10.0)
Gender	
Male	50 (50.0)
Female	50 (50.0)
Ethnicity	
White	30 (30.0)
Black	20 (20.0)
Hispanic	10 (10.0)
Asian	10 (10.0)
Other	10 (10.0)
Marital status	
Married	30 (30.0)
Single	20 (20.0)
Divorced	10 (10.0)
Widowed	10 (10.0)
Never married	10 (10.0)
Education level	
High school or less	20 (20.0)
Some college	10 (10.0)
Bachelor's degree	10 (10.0)
Master's degree	10 (10.0)
Doctorate degree	10 (10.0)
Other	10 (10.0)
Occupation	
Unemployed	10 (10.0)
Retired	10 (10.0)
Other	10 (10.0)
Health insurance	
Medicare	10 (10.0)
Medicaid	10 (10.0)
Private	10 (10.0)
Other	10 (10.0)
Other	10 (10.0)

Table 1. Demographic characteristics of the study population	
Characteristic	Frequency (%)
Age (years)	
< 18	10 (10.0)
18-24	25 (25.0)
25-34	30 (30.0)
35-44	20 (20.0)
45-54	15 (15.0)
≥ 55	10 (10.0)
Gender	
Male	45 (45.0)
Female	55 (55.0)
Ethnicity	
White	60 (60.0)
Black	20 (20.0)
Hispanic	15 (15.0)
Other	5 (5.0)
Marital status	
Married	35 (35.0)
Single	25 (25.0)
Divorced	15 (15.0)
Widowed	10 (10.0)
Education level	
High school or less	20 (20.0)
Some college	25 (25.0)
Bachelor's degree	30 (30.0)
Master's degree	15 (15.0)
PhD or higher	10 (10.0)
Annual income (\$)	
< 10,000	15 (15.0)
10,000-20,000	25 (25.0)
20,000-30,000	20 (20.0)
30,000-40,000	15 (15.0)
40,000-50,000	10 (10.0)
≥ 50,000	15 (15.0)

Blue Gel agarose beads soaked in BSA (500 ng), pTGF- β 1 (20 ng), bFGF (500 ng), hOP-1 (100 ng and 1000 ng), hOP-1/bFGF(100/100 ng) or hOP-1/pTGF- β 1 (100/5 and 100/20 ng). (A) No response: No change in the distribution of blood vessels in the surrounding CAM and about the application site. (B) Questionable response: blood vessels radiate from the surrounding CAM with more directionality toward the application site. (C) Positive response: blood vessels from the surrounding CAM converge in a spoke-like fashion about the application site. BSA = bovine serum albumin; pTGF- β 1 = platelet-derived transforming growth factor- β 1; bFGF = basic fibroblast growth factor; hOP-1 = human osteogenic protein-1. Bars, 1 mm.

Figure 2. The relative chick chorioallantoic membrane (CAM) thickness ratios in response to the application of Affigel® Blue Gel agarose beads soaked in BSA (500 ng), pTGF- β 1 (20 ng), bFGF(500 ng), hOP-1 (100 ng and 1000 ng), hOP-1/bFGF(100/100 ng) or hOP-1/pTGF- β 1 (100/5 and 100/20 ng). BSA = bovine serum albumin; pTGF- β 1 = platelet-derived transforming growth factor- β 1; bFGF = basic fibroblast growth factor; hOP-1 = human osteogenic protein-1. Values = means \pm SD, N =5 for all sample groups, $P < 0.05$ by ANOVA.

Figure 3. Cross section of a typical control-treated chick chorioallantoic membrane (CAM) following exposure to 500 ng of bovine serum albumin (BSA) for 5 days. The area in the vicinity of the beads shows normal structures with thin ectodermal (ec) and endodermal (en) epithelia enclosing the mesodermal (me) stroma. The original positions of some gel beads (g) are distinguishable by indentations in the ectodermal

surface of the CAM. The mesoderm consists primarily of sparse and loosely arranged fibroblasts in wide intercellular spaces. Occasional large blood vessels (bv) with nucleated erythrocytes are observed in the mesoderm. The ectoderm exhibits normal development of the intradermal capillaries (iec). Blue staining collagen fibers are sparsely distributed in some regions within the mesoderm. Vestiges of gelatin (gl) remain between the beads and in the regions between the beads and the stratified ectoderm. Scale bar = 50 μ m.

Figure 4. Histological response of chick chorioallantoic membrane (CAM) after the application of 20 ng pTGF- β 1. There is a distinct thickening of the mesoderm (me) and extensive stratification of the endoderm (en). A widespread proliferation of capillaries (ca) is observed throughout the mesoderm. A discrete accumulation and condensation of the fibrous connective tissue (ct), which is mainly localized in the endodermal portion of the mesoderm, accompanies the increase in the number of capillaries. Blue staining collagen fibers are densely spread in the condensed fibrous tissue within the mesoderm in the locality of the reaction center. Sloughing of the endodermal cells (arrowhead) is observed. Scale bar = 100 μ m.

Figure 5. Histological response of chick chorioallantoic membrane (CAM) after exposure to 500 ng of bFGF. There is a distinct thickening of the mesoderm (me) and extensive stratification of both the ectoderm (ec) and endoderm (en). Dense accumulations of fibroblast-rich connective tissue (ct) are localized in areas close to both the ectodermal and the endodermal portions of the mesoderm. Capillaries (ca),

as well as a large number of blue-staining collagen fibers, are spread widely throughout the reactive mesoderm. Clusters of cells (cd) with a similar appearance to the stratified ectoderm are embedded within the mesoderm. Blue staining collagen fibers are densely spread in the condensed fibrous tissue within the mesoderm in the locality of the reaction centers and finely spread in the central portion of the mesoderm. Remnants of gelatin (gl) are located between the beads and in the vicinity of the ectoderm. Scale bar = 100 μ m.

Figure 6. Histological effects induced by exposure of the chick chorioallantoic membrane (CAM) to hOP-1. (A) 100 ng of hOP-1 induced the development of multiple distended blood vessels (bv), some with nucleated erythrocytes in the lumen, in the loosely arranged mesoderm (me). Increased numbers of capillaries (ca) and a defined fibrous connective tissue (ct) aggregation, including blue staining collagen fibrils, are present within the ectodermal section of the mesoderm. Both the ectoderm (ec) and endoderm (en) are transformed into multilayered epithelia. Sloughing of the ectodermal cells (arrowheads) is clearly evident. Scale bar = 50 μ m. (B) 1000 ng of hOP-1 induced an accumulation of numerous capillaries (ca) and connective tissue fibers (ct) in the ectodermal segment of the highly expanded mesoderm (me). The ectoderm (ec) is transformed into a multilayered squamous epithelium free of blood vessels. The formerly intraectodermal capillaries are now located underneath the stratified epithelium of the ectoderm to form subepithelial capillaries (sec). The

5 embedded in the thickened mesoderm. Scale bar = 50 μm .

Figure 7. Histological reaction of a chick chorioallantoic membrane (CAM) after the application of a combination of hOP-1/bFGF (100/100 ng). Numerous distended blood vessels (bv) and capillaries (ca) with nucleated erythrocytes are widely distributed within the oedematous mesoderm (me). The fibrous connective tissue (ct), consisting of blue staining collagen fibers, is very dense and widely distributed throughout the thickness of the reactive mesoderm. The endoderm (en) and the ectoderm (ec) (not in this section) thickened by stratification. Scale bar = 50 μ m.

Figure 8. Chick chorioallantoic membrane (CAM) response following exposure to hOP-1/pTGF- β 1. (A) hOP-1/pTGF- β 1 (100/5 ng): there is a very marked thickening of all the three layers of the CAM. The multilayered endoderm (en) exhibits a villi-like pattern. Widespread capillaries (ca) and fibrous tissue (ct) are located over the entire reactive mesoderm (me) containing numerous distended blood vessels (bv). Blue staining collagen fibers are densely spread in the condensed fibrous tissue within the mesoderm in the locality of the areas adjacent to the ecto- and endoderm and finely spread in the central portion of the mesoderm. Clusters of cells (cd) with a similar appearance to the stratified ectoderm are embedded within the mesoderm. Sloughing of the endoderm (arrowheads) is clearly visible. Scale bar = 50 μ m.

(B) hOP-1/pTGF- β 1 (100/20 ng): There is extensive fibrous tissue (ct) condensation and prominently high number of capillaries (ca). Evidence of bead (g) encapsulation is clearly noticeable. The dense
5 connective tissue fibers including the blue-staining collagen, are aligned in the region skirting the zone of encapsulated beads. The multilayered endoderm (en) is villi-like and the thickened ectoderm is vessel-free. Sloughing of the endoderm (arrowhead) is clearly
10 visible. Scale bar = 100 μ m.

Figure 9. Photomicrographic evaluation of the chick chorioallantoic membrane (CAM) angiogenic response to the application of pTGF- β 1, bFGF, hOP-1, hOP-1/bFGF or hOP-1/pTGF- β 1 using Affigel® Blue Gel
15 agarose beads. N=8 for all sample groups, P<0.05 by ANOVA. BSA = bovine serum albumin; pTGF- β 1 = platelet-derived transforming growth factor- β 1; bFGF = basic fibroblast growth factor; hOP-1 = human osteogenic protein-1.

Figure 10. Qualitative ranking of chick
20 chorioallantoic membrane (CAM) angiogenic responses to the application of pTGF- β 1, bFGF, hOP-1, hOP-1/bFGF or hOP-1/pTGF- β 1 using Affi-Gel® Blue Gel agarose beads. Quantities are in nanograms. N=5 for all sample
25 groups. BSA = bovine serum albumin; pTGF- β 1 = platelet-derived transforming growth factor- β 1; bFGF = basic fibroblast growth factor; hOP-1 = human osteogenic protein-1.

DETAILED DESCRIPTION OF THE INVENTION

In order that the invention herein described may be fully understood, the following detailed description is set forth.

5 The term "biocompatible" refers to a material that does not elicit detrimental effects associated with the body's various protective systems, such as cell and humoral-associated immune responses, e.g., inflammatory responses and foreign body fibrotic
10 responses. This term also implies that no specific undesirable effects, cytotoxic or systemic, are caused by the material when it is implanted into the patient.

 The term "BMP" refers to a protein belonging to the BMP family of the TGF- β superfamily of proteins
15 defined on the basis of DNA and amino acid sequence homology. According to this invention, a protein belongs to the BMP family when it has at least 70% (e.g., at least 80% or even 85%) amino acid sequence homology with a known BMP family member within the
20 conserved C-terminal cysteine-rich domain that characterizes the BMP family. Members of the BMP family may have less than 70% DNA or amino acid sequence homology overall.

 The term "morphogenic protein" refers to a
25 protein having morphogenic activity. For instance, this protein is capable of inducing progenitor cells to proliferate and/or to initiate differentiation pathways that lead to the formation of cartilage, bone, tendon, ligament, vascular, neural or other types of tissue,
30 depending on local environmental cues. Thus, morphogenic proteins useful in this invention may behave differently in different surroundings. A

00540466 033100
OFFICE 99404560

morphogenic protein of this invention may comprise at least one polypeptide belonging to the BMP family.

The term "osteogenic protein" refers to a morphogenic protein that is capable of inducing a progenitor cell to form cartilage and/or bone. The bone may be intramembranous bone or endochondral bone. Most osteogenic proteins are members of the BMP family and are thus also BMPs. However, the converse may not be true. According to this invention, a BMP identified by sequence homology must have demonstrable osteogenic or chondrogenic activity in a functional bioassay to be an osteogenic protein.

The term "morphogenic protein stimulatory factor (MPSF)" refers to a factor that is capable of stimulating the ability of a morphogenic protein to induce tissue formation from a progenitor cell. The MPSF may have a direct or indirect effect on enhancing morphogenic protein inducing activity. For example, the MPSF may increase the bioactivity of another MPSF. Agents that increase MPSF bioactivity include, for example, those that increase the synthesis, half-life, reactivity with other biomolecules such as binding proteins and receptors, or the bioavailability of the MPSF.

The terms "morphogenic activity," "inducing activity" and "tissue inductive activity" alternatively refer to the ability of an agent to stimulate a target cell to undergo one or more cell divisions (proliferation) that may optionally lead to cell differentiation. Such target cells are referred to generically herein as progenitor cells. Cell proliferation is typically characterized by changes in

cell cycle regulation and may be detected by a number of means which include measuring DNA synthetic or cellular growth rates. Early stages of cell differentiation are typically characterized by changes in gene expression patterns relative to those of the progenitor cell; such changes may be indicative of a commitment towards a particular cell fate or cell type. Later stages of cell differentiation may be characterized by changes in gene expression patterns, cell physiology and morphology. Any reproducible change in gene expression, cell physiology or morphology may be used to assess the initiation and extent of cell differentiation induced by a morphogenic protein.

The terms "angiogenesis" and "angiogenic activity" alternatively refer to the ability of an agent to stimulate the formation of blood vessels and associated cells (including endothelial , perivascular, mesenchymal, and smooth muscle cells) and blood vessel associated basement membrane. This includes, for example of new capillary blood vessels from existent microvessels by sprouting , i.e., cellular outgrowth.

The term "synergistic interaction" refers to an interaction in which the combined effect of two or more agents is greater than the algebraic sum of their individual effects.

Provided below are detailed descriptions of suitable morphogenic proteins and morphogenic protein stimulatory factors useful in the methods of this invention. Specifically, the examples provide models for demonstrating the utility of the morphogenic proteins in inducing angiogenesis.

00750" 9940450

Morphogenic proteins

The morphogenic proteins used in the methods of this invention are capable of stimulating a progenitor cell to undergo cell division and/or differentiation. They may belong to the TGF- β protein superfamily, and include, but are not limited to, OP-1, OP-2, OP-3, BMP-2, BMP-3, BMP-3b, BMP-4, BMP-5, BMP-6, BMP-9, BMP-10, BMP-11, BMP-12, BMP-13, BMP-14, BMP-15, GDF-1, GDF-2, GDF-3, GDF-5, GDF-6, GDF-7, GDF-8, GDF-9, GDF-10, GDF-11, GDF-12, DPP, Vg-1, Vgr-1, 60A protein, NODAL, UNIVIN, SCREW, ADMP, and NEURAL. However, when the morphogenic protein is used in the absence of a morphogenic protein stimulatory factor, the morphogenic protein may not be BMP-2 or GDF-5.

In a preferred embodiment, the morphogenic protein comprises an amino acid sequence selected from the group consisting of BMP-3, BMP-4, BMP-5, BMP-6, OP-1 (BMP-7), BMP-8, BMP-9, BMP-10, BMP-11, BMP-12, BMP-13, BMP-14, BMP-15, COP-5, COP-7 and an amino acid sequence variant thereof. In a more preferred embodiment, the morphogenic protein comprises an amino acid sequence selected from the group consisting of OP-1, BMP-5, BMP-6, BMP-8, GDF-6, GDF-7 and amino acid sequence variants thereof. In a most preferred embodiment, the morphogenic protein is OP-1.

One of the preferred morphogenic proteins that is useful in this invention is OP-1. Nucleotide and amino acid sequences for hOP-1 are provided in SEQ ID NOs:1 and 2, respectively. For ease of description, hOP-1 is recited as a representative morphogenic protein. It will be appreciated by the ordinarily

skilled artisan that OP-1 is merely representative of a family of morphogens.

Other useful morphogenic proteins include polypeptides having at least 70% (e.g., at least 80% or 5 even 85%) sequence homology with a known morphogenic protein, particularly with a known BMP within the conserved C-terminal cysteine-rich domain that characterizes the BMP protein family. These morphogenic proteins include biologically active 10 variants of any known morphogenic protein, including variants containing conservative amino acid changes. For instance, useful morphogenic proteins include those containing sequences that share at least 70% amino acid sequence homology with the C-terminal seven-cysteine 15 domain of hOP-1, which domain corresponds to the C-terminal 102-106 amino acid residues of SEQ ID NO:2. The C-terminal 102 amino acid residues corresponds to residues 330-431 of SEQ ID NO:2. In one embodiment of this invention, the morphogenic protein used consists 20 of a pair of subunits disulfide-bonded to produce a dimer, wherein at least one of the subunits comprises a recombinant polypeptide belonging to the BMP family. In another embodiment of this invention, the morphogenic protein used consists of a monomeric 25 polypeptide belonging to the BMP family.

As used herein, "amino acid sequence homology" is understood to include both amino acid sequence identity and similarity. Homologous sequences share identical and/or similar amino acid residues, 30 where similar residues are conservative substitutions for, or "allowed point mutations" of, corresponding amino acid residues in an aligned reference sequence.

Thus, a candidate polypeptide sequence that shares 70% amino acid homology with a reference sequence is one in which any 70% of the aligned residues are either identical to, or are conservative substitutions of, the corresponding residues in a reference sequence.

Certain particularly preferred morphogenic polypeptides share at least 60% (e.g., at least 65%) amino acid sequence identity with the C-terminal seven-cysteine domain of human OP-1.

As used herein, "conservative substitutions" are residues that are physically or functionally similar to the corresponding reference residues. That is, a conservative substitution and its reference residue have similar size, shape, electric charge, chemical properties including the ability to form covalent or hydrogen bonds, or the like. Preferred conservative substitutions are those fulfilling the criteria defined for an accepted point mutation in Dayhoff et al., Atlas of Protein Sequence and Structure, 5, pp. 345-362 (1978 & Supp.). Examples of conservative substitutions are substitutions within the following groups: (a) valine, glycine; (b) glycine, alanine; (c) valine, isoleucine, leucine; (d) aspartic acid, glutamic acid; (e) asparagine, glutamine; (f) serine, threonine; (g) lysine, arginine, methionine; and (h) phenylalanine, tyrosine. The term "conservative variant" or "conservative variation" also includes the use of a substituting amino acid residue in place of an amino acid residue in a given parent amino acid sequence, where antibodies specific for the parent sequence are also specific for, i.e., "cross-

0054046 0340

react" or "immuno-react" with, the resulting substituted polypeptide sequence.

Amino acid sequence homology can be determined by methods well known in the art. For instance, to determine the percent homology of a candidate amino acid sequence to the sequence of the seven-cysteine domain, the two sequences are first aligned. The alignment can be made with, e.g., the dynamic programming algorithm described in Needleman et al., J. Mol. Biol., 48, p. 443 (1970), and the Align Program, a commercial software package produced by DNASTar, Inc. The teachings by both sources are incorporated by reference herein. An initial alignment can be refined by comparison to a multi-sequence alignment of a family of related proteins. Once the alignment is made and refined, a percent homology score is calculated. The aligned amino acid residues of the two sequences are compared sequentially for their similarity to each other. Similarity factors include similar size, shape and electrical charge. One particularly preferred method of determining amino acid similarities is the PAM250 matrix described in Dayhoff et al., *supra*. A similarity score is first calculated as the sum of the aligned pairwise amino acid similarity scores. Insertions and deletions are ignored for the purposes of percent homology and identity. Accordingly, gap penalties are not used in this calculation. The raw score is then normalized by dividing it by the geometric mean of the scores of the candidate sequence and the seven-cysteine domain. The geometric mean is the square root of the product of

004046-03400

these scores. The normalized raw score is the percent homology.

007EE0" 9940456 033100

Morphogenic proteins useful herein include any known naturally occurring native proteins, including allelic, phylogenetic counterparts and other variants thereof. These variants include forms having varying glycosylation patterns, varying N-termini, and active truncated or mutated forms of a native protein. Useful morphogenic proteins also include those that are biosynthetically produced (e.g., "muteins" or "mutant proteins") and those that are new, morphogenically active members of the general morphogenic family of proteins. Particularly useful sequences include those comprising the C-terminal 96 to 102 amino acid residues of: DPP (from *Drosophila*), Vg-1 (from *Xenopus*), Vgr-1 (from mouse), the OP1 and OP2 proteins (U.S. Patent No. 5,011,691), as well as the proteins referred to as BMP-2, BMP-3, BMP-4 (WO 88/00205, U.S. Patent No. 5,013,649 and WO 91/18098), BMP-5 and BMP-6 (WO 90/11366), BMP-8 and BMP-9. Other proteins useful in the practice of the invention include active forms of OP1, OP2, OP3, BMP-2, BMP-3, BMP-3b, BMP-4, BMP-5, BMP-6, BMP-9, BMP-10, BMP-11, BMP-12, BMP-13, BMP-14, BMP-15, DPP, Vg-1, Vgr-1, 60A protein, GDF-1, GDF-2, GDF-3, GDF-5, GDF-6, GDF-7, GDF-8, GDF-9, and GDF-10, GDF-11, GDF-12, GDF-13, UNIVIN, NODAL, SCREW, ADMP, and NEURAL. However, when the morphogenic protein is used in the absence of a morphogenic protein stimulatory factor, the morphogenic protein may not be BMP-2 or GDF-5.

Osteogenic proteins useful as morphogenic proteins of this invention include those containing

sequences that share greater than 60% identity with the seven-cysteine domain. In other embodiments, useful osteogenic proteins are defined as osteogenically active proteins having any one of the generic sequences defined herein, including OPX (SEQ ID NO:3) and Generic Sequences 7 (SEQ ID NO:4), 8 (SEQ ID NO:5), 9 (SEQ ID NO:6) and 10 (SEQ ID NO:7).

Generic Sequence 7 (SEQ ID NO:4) and Generic Sequence 8 (SEQ ID NO:5), disclosed below, accommodate the homologies shared among preferred protein family members identified to date, including OP-1, OP-2, OP-3, BMP-2, BMP-3, BMP-4, BMP-5, BMP-6, 60A, DPP, Vg-1, Vgr-1, and GDF-1. The amino acid sequences for these proteins are described herein and/or in the art. The generic sequences include the identical amino acid residues shared by these sequences in the C-terminal six- or seven-cysteine skeletal domains (represented by Generic Sequences 7 and 8, respectively), as well as alternative residues for the variable positions within the sequences. The generic sequences provide an appropriate cysteine skeleton where inter- or intra-molecular disulfide bonds can form. Those sequences contain certain specified amino acids that may influence the tertiary structure of the folded proteins. In addition, the generic sequences allow for an additional cysteine at position 36 (Generic Sequence 7) or position 41 (Generic Sequence 8), thereby encompassing the biologically active sequences of OP-2 and OP-3.

Leu or Tyr); Xaa at res.33 = (Leu, Val or Met); Xaa at
res.34 = (Asn, Asp, Ala, Thr or Pro); Xaa at res.35 =
(Ser, Asp, Glu, Leu, Ala or Lys); Xaa at res.36 = (Tyr,
Cys, His, Ser or Ile); Xaa at res.37 = (Met, Phe, Gly
5 or Leu); Xaa at res.38 = (Asn, Ser or Lys); Xaa at
res.39 = (Ala, Ser, Gly or Pro); Xaa at res.40 = (Thr,
Leu or Ser); Xaa at res.44 = (Ile, Val or Thr); Xaa at
res.45 = (Val, Leu, Met or Ile); Xaa at res.46 = (Gln
or Arg); Xaa at res.47 = (Thr, Ala or Ser); Xaa at
10 res.48 = (Leu or Ile); Xaa at res.49 = (Val or Met);
Xaa at res.50 = (His, Asn or Arg); Xaa at res.51 =
(Phe, Leu, Asn, Ser, Ala or Val); Xaa at res.52 = (Ile,
Met, Asn, Ala, Val, Gly or Leu); Xaa at res.53 = (Asn,
Lys, Ala, Glu, Gly or Phe); Xaa at res.54 = (Pro, Ser
15 or Val); Xaa at res.55 = (Glu, Asp, Asn, Gly, Val, Pro
or Lys); Xaa at res.56 = (Thr, Ala, Val, Lys, Asp, Tyr,
Ser, Gly, Ile or His); Xaa at res.57 = (Val, Ala or
Ile); Xaa at res.58 = (Pro or Asp); Xaa at res.59 =
(Lys, Leu or Glu); Xaa at res.60 = (Pro, Val or Ala);
20 Xaa at res.63 = (Ala or Val); Xaa at res.65 = (Thr, Ala
or Glu); Xaa at res.66 = (Gln, Lys, Arg or Glu); Xaa at
res.67 = (Leu, Met or Val); Xaa at res.68 = (Asn, Ser,
Asp or Gly); Xaa at res.69 = (Ala, Pro or Ser); Xaa at
res.70 = (Ile, Thr, Val or Leu); Xaa at res.71 = (Ser,
25 Ala or Pro); Xaa at res.72 = (Val, Leu, Met or Ile);
Xaa at res.74 = (Tyr or Phe); Xaa at res.75 = (Phe,
Tyr, Leu or His); Xaa at res.76 = (Asp, Asn or Leu);
Xaa at res.77 = (Asp, Glu, Asn, Arg or Ser); Xaa at
res.78 = (Ser, Gln, Asn, Tyr or Asp); Xaa at res.79 =
30 (Ser, Asn, Asp, Glu or Lys); Xaa at res.80 = (Asn, Thr
or Lys); Xaa at res.82 = (Ile, Val or Asn); Xaa at
res.84 = (Lys or Arg); Xaa at res.85 = (Lys, Asn, Gln,

00446" 9904560

5

10

25

30

accommodates the C-terminal six-cysteine skeleton and,
like Generic Sequence 8, Generic Sequence 10
accommodates the C-terminal seven-cysteine skeleton.

GENERIC SEQUENCE 9

```

5      Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa
      1              5              10
Xaa Xaa Xaa Xaa Pro Xaa Xaa Xaa Xaa Xaa Xaa Xaa Cys Xaa
      15              20              25
Gly Xaa Cys Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa
10      30              35              40
Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa
      45              50
Xaa Xaa Xaa Xaa Xaa Xaa Xaa Cys Xaa Pro Xaa Xaa Xaa Xaa
55      60              65
15 Xaa Xaa Xaa Xaa Leu Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa
      70              75              80
Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Cys Xaa Cys
      85              90              95
Xaa (SEQ ID NO:6)

```

20 wherein each Xaa is independently defined as follows:
Xaa at res.1 = (Phe, Leu or Glu); Xaa at res.2 = (Tyr,
Phe, His, Arg, Thr, Lys, Gln, Val or Glu); Xaa at res.3
= (Val, Ile, Leu or Asp); Xaa at res.4 = (Ser, Asp,
Glu, Asn or Phe); Xaa at res.5 = (Phe or Glu); Xaa at
25 res.6 = (Arg, Gln, Lys, Ser, Glu, Ala or Asn); Xaa at
res.7 = (Asp, Glu, Leu, Ala or Gln); Xaa at res.8 =
(Leu, Val, Met, Ile or Phe); Xaa at res.9 = (Gly, His
or Lys); Xaa at res.10 = (Trp or Met); Xaa at res.11 =
(Gln, Leu, His, Glu, Asn, Asp, Ser or Gly); Xaa at
30 res.12 = (Asp, Asn, Ser, Lys, Arg, Glu or His); Xaa at
res.13 = (Trp or Ser); Xaa at res.14 = (Ile or Val);

Xaa at res.15 = (Ile or Val); Xaa at res.16 = (Ala, Ser, Tyr or Trp); Xaa at res.18 = (Glu, Lys, Gln, Met, Pro, Leu, Arg, His or Lys); Xaa at res.19 = (Gly, Glu, Asp, Lys, Ser, Gln, Arg or Phe); Xaa at res.20 = (Tyr or Phe); Xaa at res.21 = (Ala, Ser, Gly, Met, Gln, His, Glu, Asp, Leu, Asn, Lys or Thr); Xaa at res.22 = (Ala or Pro); Xaa at res.23 = (Tyr, Phe, Asn, Ala or Arg); Xaa at res.24 = (Tyr, His, Glu, Phe or Arg); Xaa at res.26 = (Glu, Asp, Ala, Ser, Tyr, His, Lys, Arg, Gln or Gly); Xaa at res.28 = (Glu, Asp, Leu, Val, Lys, Gly, Thr, Ala or Gln); Xaa at res.30 = (Ala, Ser, Ile, Asn, Pro, Glu, Asp, Phe, Gln or Leu); Xaa at res.31 = (Phe, Tyr, Leu, Asn, Gly or Arg); Xaa at res.32 = (Pro, Ser, Ala or Val); Xaa at res.33 = (Leu, Met, Glu, Phe or Val); Xaa at res.34 = (Asn, Asp, Thr, Gly, Ala, Arg, Leu or Pro); Xaa at res.35 = (Ser, Ala, Glu, Asp, Thr, Leu, Lys, Gln or His); Xaa at res.36 = (Tyr, His, Cys, Ile, Arg, Asp, Asn, Lys, Ser, Glu or Gly); Xaa at res.37 = (Met, Leu, Phe, Val, Gly or Tyr); Xaa at res.38 = (Asn, Glu, Thr, Pro, Lys, His, Gly, Met, Val or Arg); Xaa at res.39 = (Ala, Ser, Gly, Pro or Phe); Xaa at res.40 = (Thr, Ser, Leu, Pro, His or Met); Xaa at res.41 = (Asn, Lys, Val, Thr or Gln); Xaa at res.42 = (His, Tyr or Lys); Xaa at res.43 = (Ala, Thr, Leu or Tyr); Xaa at res.44 = (Ile, Thr, Val, Phe, Tyr, Met or Pro); Xaa at res.45 = (Val, Leu, Met, Ile or His); Xaa at res.46 = (Gln, Arg or Thr); Xaa at res.47 = (Thr, Ser, Ala, Asn or His); Xaa at res.48 = (Leu, Asn or Ile); Xaa at res.49 = (Val, Met, Leu, Pro or Ile); Xaa at res.50 = (His, Asn, Arg, Lys, Tyr or Gln); Xaa at res.51 = (Phe, Leu, Ser, Asn, Met, Ala, Arg, Glu, Gly or Gln); Xaa at res.52 = (Ile, Met, Leu, Val, Lys, Gln

Ala or Tyr); Xaa at res.53 = (Asn, Phe, Lys, Glu, Asp, Ala, Gln, Gly, Leu or Val); Xaa at res.54 = (Pro, Asn, Ser, Val or Asp); Xaa at res.55 = (Glu, Asp, Asn, Lys, Arg, Ser, Gly, Thr, Gln, Pro or His); Xaa at res.56 =
5 (Thr, His, Tyr, Ala, Ile, Lys, Asp, Ser, Gly or Arg); Xaa at res.57 = (Val, Ile, Thr, Ala, Leu or Ser); Xaa at res.58 = (Pro, Gly, Ser, Asp or Ala); Xaa at res.59 = (Lys, Leu, Pro, Ala, Ser, Glu, Arg or Gly); Xaa at res.60 = (Pro, Ala, Val, Thr or Ser); Xaa at res.61 =
10 (Cys, Val or Ser); Xaa at res.63 = (Ala, Val or Thr); Xaa at res.65 = (Thr, Ala, Glu, Val, Gly, Asp or Tyr); Xaa at res.66 = (Gln, Lys, Glu, Arg or Val); Xaa at res.67 = (Leu, Met, Thr or Tyr); Xaa at res.68 = (Asn, Ser, Gly, Thr, Asp, Glu, Lys or Val); Xaa at res.69 =
15 (Ala, Pro, Gly or Ser); Xaa at res.70 = (Ile, Thr, Leu or Val); Xaa at res.71 = (Ser, Pro, Ala, Thr, Asn or Gly); Xaa at res.72 = (Val, Ile, Leu or Met); Xaa at res.74 = (Tyr, Phe, Arg, Thr, Tyr or Met); Xaa at res.75 = (Phe, Tyr, His, Leu, Ile, Lys, Gln or Val);
20 Xaa at res.76 = (Asp, Leu, Asn or Glu); Xaa at res.77 = (Asp, Ser, Arg, Asn, Glu, Ala, Lys, Gly or Pro); Xaa at res.78 = (Ser, Asn, Asp, Tyr, Ala, Gly, Gln, Met, Glu, Asn or Lys); Xaa at res.79 = (Ser, Asn, Glu, Asp, Val, Lys, Gly, Gln or Arg); Xaa at res.80 = (Asn, Lys, Thr, Pro, Val, Ile, Arg, Ser or Gln); Xaa at res.81 = (Val, Ile, Thr or Ala); Xaa at res.82 = (Ile, Asn, Val, Leu, Tyr, Asp or Ala); Xaa at res.83 = (Leu, Tyr, Lys or Ile); Xaa at res.84 = (Lys, Arg, Asn, Tyr, Phe, Thr, Glu or Gly); Xaa at res.85 = (Lys, Arg, His, Gln, Asn, Glu or Val); Xaa at res.86 = (Tyr, His, Glu or Ile);
30 Xaa at res.87 = (Arg, Glu, Gln, Pro or Lys); Xaa at res.88 = (Asn, Asp, Ala, Glu, Gly or Lys); Xaa at

res.89 = (Met or Ala); Xaa at res.90 = (Val, Ile, Ala, Thr, Ser or Lys); Xaa at res.91 = (Val or Ala); Xaa at res.92 = (Arg, Lys, Gln, Asp, Glu, Val, Ala, Ser or Thr); Xaa at res.93 = (Ala, Ser, Glu, Gly, Arg or Thr);
5 Xaa at res.95 = (Gly, Ala or Thr); and Xaa at res.97 = (His, Arg, Gly, Leu or Ser). Further, after res.53 in rat BMP3b and mGDF-10 there is an Ile; after res.54 in GDF-1 there is a Thr; after res.54 in BMP3 there is a Val; after res.78 in BMP-8 and DORSALIN there is a Gly;
10 after res.37 in hGDF-1 there are Pro, Gly, Gly, and Pro.

Generic Sequence 10 (SEQ ID NO:7) includes all of Generic Sequence 9 and in addition includes the following five amino acid residues at its N-terminus:
15 Cys Xaa Xaa Xaa Xaa (SEQ ID NO:9), wherein Xaa at res.2 = (Lys, Arg, Gln, Ser, His, Glu, Ala, or Cys); Xaa at res.3 = (Lys, Arg, Met, Lys, Thr, Leu, Tyr, or Ala); Xaa at res.4 = (His, Gln, Arg, Lys, Thr, Leu, Val, Pro, or Tyr); and Xaa at res.5 = (Gln, Thr, His, Arg, Pro, Ser, Ala, Gln, Asn, Tyr, Lys, Asp, or Leu).
20 Accordingly, beginning at res.6, each "Xaa" in Generic Sequence 10 is a specified amino acid defined as for Generic Sequence 9, with the distinction that each residue number described for Generic Sequence 9 is
25 shifted by five in Generic Sequence 10. For example, "Xaa at res.1 = (Phe, Leu or Glu)" in Generic Sequence 9 corresponds to Xaa at res.6 in Generic Sequence 10.

As noted above, certain preferred bone morphogenic proteins useful in this invention have
30 greater than 60%, preferably greater than 65%, identity with the C-terminal seven-cysteine domain of hOP-1. These particularly preferred sequences include allelic

and phylogenetic variants of the OP-1 and OP-2 proteins, including the *Drosophila* 60A protein. Accordingly, in certain particularly preferred embodiments, useful proteins include active proteins comprising dimers having the generic amino acid sequence "OPX" (SEQ ID NO:3), which defines the seven-cysteine skeleton and accommodates the homologies between several identified variants of OP-1 and OP-2. Each Xaa in OPX is independently selected from the residues occurring at the corresponding position in the C-terminal sequence of mouse or human OP-1 or OP-2.

OPX

	Cys	Xaa	Xaa	His	Glu	Leu	Tyr	Val	Ser	Phe	Xaa	Asp	Leu	Gly
	1				5					10				
15	Trp	Xaa	Asp	Trp	Xaa	Ile	Ala	Pro	Xaa	Gly	Tyr	Xaa	Ala	Tyr
	15					20					25			
	Tyr	Cys	Glu	Gly	Glu	Cys	Xaa	Phe	Pro	Leu	Xaa	Ser	Xaa	Met
		30					35					40		
	Asn	Ala	Thr	Asn	His	Ala	Ile	Xaa	Gln	Xaa	Leu	Val	His	Xaa
20			45					50					55	
	Xaa	Xaa	Pro	Xaa	Xaa	Val	Pro	Lys	Xaa	Cys	Cys	Ala	Pro	Thr
				60					65					70
	Xaa	Leu	Xaa	Ala	Xaa	Ser	Val	Leu	Tyr	Xaa	Asp	Xaa	Ser	Xaa
					75					80				
25	Asn	Val	Ile	Leu	Xaa	Lys	Xaa	Arg	Asn	Met	Val	Val	Xaa	Ala
	85					90					95			
	Cys	Gly	Cys	His	(SEQ ID NO:3)									
					100									

0044046-03400

wherein Xaa at res.2 = (Lys or Arg); Xaa at res.3 =
(Lys or Arg); Xaa at res.11 = (Arg or Gln); Xaa at
res.16 = (Gln or Leu); Xaa at res.19 = (Ile or Val);
Xaa at res.23 = (Glu or Gln); Xaa at res.26 = (Ala or
5 Ser); Xaa at res.35 = (Ala or Ser); Xaa at res.39 =
(Asn or Asp); Xaa at res.41 = (Tyr or Cys); Xaa at
res.50 = (Val or Leu); Xaa at res.52 = (Ser or Thr);
Xaa at res.56 = (Phe or Leu); Xaa at res.57 = (Ile or
Met); Xaa at res.58 = (Asn or Lys); Xaa at res.60 =
10 (Glu, Asp or Asn); Xaa at res.61 = (Thr, Ala or Val);
Xaa at res.65 = (Pro or Ala); Xaa at res.71 = (Gln or
Lys); Xaa at res.73 = (Asn or Ser); Xaa at res.75 =
(Ile or Thr); Xaa at res.80 = (Phe or Tyr); Xaa at
res.82 = (Asp or Ser); Xaa at res.84 = (Ser or Asn);
15 Xaa at res.89 = (Lys or Arg); Xaa at res.91 = (Tyr or
His); and Xaa at res.97 = (Arg or Lys).

In another embodiment, the morphogenic
proteins used in the methods of this invention comprise
species of the generic amino acid sequence

20 1 10 20 30 40 50
CXXXXLXVXFVFXDXGWXXWXXXPXGXXAXY**CXGX**CXXPXXXXXXXXXNHAXX
60 70 80 90 100
QXXVXXXNXXXXPXX**CC**XPXXXXXXXXLXXXXXXXXVXLXXYXXMXVXX**CXCX**
(SEQ ID NO:10)

25 or residues 6-102 of SEQ ID NO:10, where the letters
indicate the amino acid residues of standard single
letter code, and the Xs represent any amino acid
residues. Cysteine residues are highlighted.

Preferred amino acid sequences within the
30 foregoing generic sequence (SEQ ID NO:10) are:

```

1          10          20          30          40          50
  LYVDFRDVGWNDWIVAPPGYHAFYCHGECPFPLADHLNSTNHAIV
    K S S L  QE VIS E FD Y  E A AY MPESMKAS  VI
    F E K I  DN   L   N S  Q  ITK F P   TL
5          A      S      K

          60          70          80          90          100
  QTLVNSVNP GKIPKACCVPTELSAISMLYLDENENVVLKNYQDMVVEGCGCR
  SI HAI SEQV EP   EQMNSLAI FFNDQDK I RK EE T DA H H
10    RF  T  S    K DPV V  Y N S    H RN  RS
    N    S                K      P    E

```

and

```

1          10          20          30          40          50
  CKRHPLYVDFRDVGWNDWIVAPPGYHAFYCHGECPFPLADHLNSTNHAIV
15  RRRS K S S L  QE VIS E FD Y  E A AY MPESMKAS  VI
    KE F E K I  DN   L   N S  Q  ITK F P   TL
  Q          A      S      K

          60          70          80          90          100
  QTLVNSVNP GKIPKACCVPTELSAISMLYLDENENVVLKNYQDMVVEGCGCR
20  SI HAI SEQV EP   EQMNSLAI FFNDQDK I RK EE T DA H H
    RF  T  S    K DPV V  Y N S    H RN  RS
    N    S                K      P    E

```

wherein each of the amino acids arranged vertically at each position in the sequence may be used alternatively in various combinations (SEQ ID NO:10). These generic sequences have 6 or 7 cysteine residues where inter- or intra-molecular disulfide bonds can form. These sequences also contain other critical amino acids that influence the tertiary structure of the proteins.

In still another embodiment, useful morphogenic proteins comprise an amino acid sequence encoded by a nucleic acid that hybridizes, under low, medium or high stringency hybridization conditions, to DNA or RNA encoding reference morphogenic protein coding sequences. Exemplary reference sequences

include the C-terminal sequences defining the conserved seven-cysteine domains of OP-1, OP-2, BMP-4, BMP-5, BMP-6, 60A, GDF-3, GDF-5, GDF-6, GDF-7, and the like. High stringent hybridization conditions are herein
5 defined as hybridization in 40% formamide, 5X SSPE, 5X Denhardt's Solution, and 0.1% SDS at 37°C overnight, and washing in 0.1X SSPE, 0.1% SDS at 50°C. Standard stringency conditions are well characterized in commercially available, standard molecular cloning
10 texts. See, for example, Molecular Cloning, A Laboratory Manual, 2nd Ed., ed. by Sambrook et al. (Cold Spring Harbor Laboratory Press 1989); DNA Cloning, Volumes I and II (D. N. Glover ed., 1985); Oligonucleotide Synthesis (M. J. Gait ed., 1984);
15 Nucleic Acid Hybridization (B. D. Hames & S. J. Higgins eds. 1984); and B. Perbal, A Practical Guide To Molecular Cloning (1984).

Suitable *in vitro*, *ex vivo* and *in vivo* bioassays known in the art, including those described
20 herein, may be used to ascertain whether a new BMP-related gene product has a morphogenic activity. Expression and localization studies defining where and when the gene is expressed may also be used to identify potential morphogenic activities. Nucleic acid and
25 protein localization procedures are well known to those of skill in the art (see, e.g., Ausubel et al., eds. Current Protocols in Molecular Cloning, Greene Publishing and Wiley Interscience, New York, 1989).

Many of the identified BMPs are osteogenic
30 and can induce bone and cartilage formation when implanted into mammals. Some BMPs identified based on sequence homology to known osteogenic proteins possess

other morphogenic activities such as angiogenic activity and the MPSFs according to this invention may be used to enhance those activities.

That osteogenic proteins originally derived from bone matrix are involved in angiogenesis suggests that these and other members of the BMP family have additional tissue inductive properties that are not yet disclosed. It is envisioned that the MPSFs set forth in this invention can be used to enhance new or known tissue inductive properties of various known morphogenic proteins. It is also envisioned that the invention described herein will be useful for stimulating tissue inductive activities of new morphogenic proteins as they are identified in the future.

Production of Morphogenic Proteins

The morphogenic proteins of this invention can be derived from a variety of sources. For instance, they may be isolated from natural sources, recombinantly produced, or chemically synthesized.

1. Naturally Derived Morphogenic Proteins

The morphogenic proteins used in this invention can be purified from tissue sources, e.g., mammalian tissue sources, using well known techniques. See, e.g., Oppermann et al., U.S. Patent Nos. 5,324,819 and 5,354,557. If a purification protocol is unpublished, as for a newly identified morphogenic protein, conventional protein purification techniques (e.g., immunoaffinity) may be performed in combination with morphogenic activity assays. Such assays allow

the trace of the morphogenic activity through a series of purification steps.

2. Recombinantly Expressed Morphogenic Proteins

In another embodiment of this invention, the morphogenic protein used in this invention is produced by expressing an appropriate recombinant DNA molecule in a host cell. The DNA and amino acid sequences of many BMPs and OPs have been reported, and methods for their recombinant production are published and otherwise known to those of skill in the art. For a general discussion of cloning and recombinant DNA technology, see Ausubel et al., *supra*; see also Watson et al., Recombinant DNA, 2d ed. 1992 (W.H. Freeman and Co., New York).

The DNA sequences encoding bovine and human BMP-2 (formerly BMP-2A) and BMP-4 (formerly BMP-2B), and processes for recombinantly producing the corresponding proteins are described in U.S. Patent Nos. 5,011,691, 5,013,649, 5,166,058 and 5,168,050. The DNA and amino acid sequences of human and bovine BMP-5 and BMP-6, and methods for their recombinant production, are disclosed in U.S. Patent Nos. 5,106,748, and 5,187,076, respectively; see also U.S. Patent Nos. 5,011,691 and 5,344,654. Methods for OP-1 recombinant expression are disclosed in Oppermann et al., U.S. Patent Nos. 5,011,691 and 5,258,494. For an alignment of BMP-2, BMP-4, BMP-5, BMP-6 and OP-1 (BMP-7) amino acid sequences, see WO 95/16034. DNA sequences encoding BMP-8 are disclosed in WO 91/18098, and DNA sequences encoding BMP-9 in WO 93/00432. DNA and deduced amino acid sequences encoding BMP-10 and BMP-11 are disclosed in WO 94/26893, and WO 94/26892,

respectively. DNA and deduced amino acid sequences for BMP-12 and BMP-13 are disclosed in WO 95/16035. The above patent disclosures, which describe DNA and amino acid sequences, and methods for producing the BMPs and
5 OPs encoded by those sequences, are incorporated herein by reference.

To clone genes that encode new BMPs, OPs and other morphogenic proteins identified in extracts by bioassay, methods entailing "reverse genetics" may be
10 employed. Such methods start with a protein of known or unknown function to obtain the gene that encodes that protein. Standard protein purification techniques may be used as an initial step. If enough protein can be purified to obtain a partial amino acid sequence, a
15 degenerate DNA probe capable of hybridizing to the DNA sequence that encodes that partial amino acid sequence may be designed, synthesized and used as a probe to isolate full-length clones that encode that or a related morphogenic protein.

Alternatively, a partially-purified extract
20 containing the morphogenic protein may be used to raise antibodies directed against that protein. Morphogenic protein-specific antibodies may then be used as a probe to screen expression libraries made from cDNAs (see,
25 e.g., Broome and Gilbert, Proc. Natl. Acad. Sci. U.S.A., 75, pp. 2746-49 (1978); Young and Davis, Proc. Natl. Acad. Sci. U.S.A., 80, pp. 31-35 (1983)).

For cloning and expressing new BMPs, OPs and other morphogenic proteins identified based on DNA
30 sequence homology, the homologous sequences may be cloned and sequenced using standard recombinant DNA techniques. With the DNA sequence available, a DNA

00750" 9940450

fragment encoding the morphogenic protein may be inserted into an expression vector selected to work in conjunction with a desired host expression system. The DNA fragment is cloned into the vector such that its transcription is controlled by a heterologous promoter in the vector, preferably a promoter which may be optionally regulated.

Some host-vector systems appropriate for the recombinant expression of BMPs and OPs are disclosed in the references cited above. Useful host cells include but are not limited to bacteria such as *E. coli*, yeasts such as *Saccharomyces* and *Picia*, insects cells and other primary, transformed or immortalized eukaryotic cultured cells. Preferred eukaryotic host cells include CHO, COS and BSC cells (see below).

An appropriate vector is selected according to the host system selected. Useful vectors include but are not limited to plasmids, cosmids, bacteriophage, insect and animal viral vectors, including those derived from retroviruses and other single and double-stranded DNA viruses.

In one embodiment, the morphogenic protein used in the method of this invention may be derived from a recombinant DNA molecule expressed in a prokaryotic host. Using recombinant DNA techniques, various fusion genes have been constructed to induce recombinant expression of naturally sourced osteogenic sequences in *E. coli* (see, e.g., Oppermann et al., U. S. Patent No. 5,354,557, incorporated herein by reference). Using analogous procedures, DNAs comprising truncated forms of naturally sourced morphogenic sequences may be prepared as fusion

constructs linked by a sequence coding for the acid labile cleavage site (Asp-Pro) to a leader sequence (such as the "MLE leader") suitable for promoting expression in *E. coli*.

5 In another embodiment, the morphogenic protein used in this invention is expressed using a mammalian host-vector system (e.g., transgenic production or tissue culture production). A morphogenic protein so expressed may resemble more
10 closely the naturally occurring protein. While the glycosylation pattern of the recombinant protein may sometimes differ from that of the natural protein, such differences are often not essential for biological activity of the recombinant protein. Techniques for
15 transfection, expression and purification of recombinant proteins are well known in the art. See, e.g., Ausubel et al., *supra*, and Bendig, Genetic Engineering, 7, pp. 91-127 (1988).

 Mammalian DNA vectors should include
20 appropriate sequences to promote expression of the gene of interest. Such sequences include transcription initiation, termination and enhancer sequences; efficient RNA processing signals such as splicing and polyadenylation signals; mRNA-stabilizing sequences;
25 translation-enhancing sequences (e.g., Kozak consensus sequence); protein-stabilizing sequences; and when desired, sequences that enhance protein secretion.

 Restriction maps and sources of various exemplary expression vectors designed for OP-1
30 expression in mammalian cells have been described in U.S. Patent No. 5,354,557. Each of these vectors employs a full-length hOP-1 cDNA sequence inserted into

00760" 99404560

the pUC-18 vector. It will be appreciated by those of skill in the art that DNA sequences encoding truncated forms of morphogenic proteins may also be used, provided that the expression vector or host cell provides the sequences necessary to direct processing and secretion of the expressed protein.

Useful promoters include, but are not limited to, the SV40 early and late promoters, the adenovirus major late promoter, the mouse metallothionein-I ("mMT") promoter, the Rous sarcoma virus ("RSV") long terminal repeat ("LTR"), the mouse mammary tumor virus ("MMTV") LTR, and the human cytomegalovirus ("CMV") major intermediate-early promoter. For instance, a combination of the CMV or MMTV promoter with an enhancer sequence from the RSV LTR has been found to be particularly useful in expressing human osteogenic proteins.

Preferred DNA vectors also include a marker gene (e.g., neomycin or DHFR) and means for amplifying the copy number of the gene of interest. DNA vectors may also comprise stabilizing sequences (e.g., ori- or ARS-like sequences and telomere-like sequences), or may alternatively be designed to favor directed or non-directed integration into the host cell genome.

One method of gene amplification in mammalian cell systems is the use of the selectable dihydrofolate reductase (DHFR) gene in a dhfr⁻ cell line. Generally, the DHFR gene is provided on the vector carrying the gene of interest, and addition of increasing concentrations of the cytotoxic drug methotrexate (MTX) leads to amplification of the DHFR gene copy number, as well as that of the gene physically associated with it.

5

10

25

30

(COS) provide high levels of transient gene expression and are thus useful for rapidly testing vector construction and the expression of cloned genes. COS cells expressing the gene of interest can be
5 established by transfecting the cells with, e.g., an SV40 vector carrying the gene. Stably transfected cell lines, on the other hand, can be used for long term production of morphogenic proteins. By way of example, both CHO cells and BSC40-tsA58 cells can be used as
10 host cells. Recombinant OP-1 has been expressed in three different cell expression systems: COS cells for rapidly screening the functionality of the various expression constructs, CHO cells for the establishment of stable cell lines, and BSC40-tsA58 cells as an
15 alternative means of producing recombinant OP-1 protein.

Several bone-derived osteogenic proteins (OPs) and BMPs are found as homo- and heterodimers comprising interchain disulfide bonds in their active
20 forms. For instance, BMP-4, BMP-6 and BMP-7 (OP-1) -- originally isolated from bone -- are bioactive as either homodimers or heterodimers. The ability of OPs and BMPs to form heterodimers may confer additional or altered morphogenic activities on morphogenic proteins.
25 Heterodimers may exhibit qualitatively or quantitatively different binding affinities than homodimers for OP and BMP receptors. Altered binding affinities may in turn result in differential activation of receptors that mediate different
30 signalling pathways, ultimately leading to different biological activities. Altered binding affinities can also be manifested in a tissue or cell type-specific

manner, thereby inducing only particular progenitor cell types to undergo proliferation and/or differentiation.

The dimeric proteins can be isolated from the culture media and/or refolded and dimerized *in vitro* to form biologically active compositions. Heterodimers can be formed *in vitro* by combining separate, distinct polypeptide chains. Alternatively, heterodimers can be formed in a single cell by co-expressing nucleic acids encoding separate, distinct polypeptide chains. See, e.g., WO 93/09229 and U.S. Patent No. 5,411,941, for exemplary protocols for heterodimer protein production.

Synthetic Non-native Morphogenic Proteins

In another embodiment, a morphogenic protein used in the method of this invention may be prepared synthetically. Morphogenic proteins prepared synthetically may be native, or may be non-native proteins, i.e., those not otherwise found in nature.

Non-native morphogenic proteins can be made by mutating native morphogenic proteins. Methods for making mutations that favor refolding and/or assembling subunits into forms that exhibit greater morphogenic activity have been described. See, e.g., U.S. Patent No. 5,399,677.

Non-native morphogenic proteins can also be synthesized using a series of consensus sequences (U. S. Patent No. 5,324,819). These consensus sequences were designed based on partial amino acid sequence data obtained from native osteogenic products and on their homologies with other proteins reportedly having a presumed or demonstrated developmental function.

Several biosynthetic consensus sequences (called
consensus osteogenic proteins or "COPs") have been
expressed as fusion proteins in prokaryotes. Purified
fusion proteins may be cleaved, refolded, combined with
5 a hormone and a soluble receptor thereof, implanted in
an established animal model and examined for their
bone- and/or cartilage-inducing activity. Certain
preferred synthetic osteogenic proteins comprise one or
both of two synthetic amino acid sequences designated
10 COP5 and COP7.

The amino acid sequences of COP5 and COP7 are
shown below, as set forth in Oppermann et al., U. S.
Patent Nos. 5,011,691 and 5,324,819, which are
incorporated herein by reference:

15 COP5 LYVDFS-DVGW**DD**WIVAPPGY**Q**AFYCHGECPFPLAD
COP7 LYVDFS-DVGW**ND**WIVAPPGY**H**AFYCHGECPFPLAD

COP5 **H**FNSTN--H-AVVQTLVNSVNSKI--PKACCVPTELSA
COP7 **H**LNSTN--H-AVVQTLVNSVNSKI--PKACCVPTELSA

COP5 ISMLYLDENEKVVVLKYNQEMVVEGCGCR
20 COP7 ISMLYLDENEKVVVLKYNQEMVVEGCGCR

In these amino acid sequences, the dashes (-)
are used as fillers only to line up comparable
sequences in related proteins. Differences between the
aligned amino acid sequences are highlighted.

25 In one embodiment, the morphogenic protein
used in the method of this invention is a synthetic
osteogenic protein comprising a partial or complete

sequence of a generic sequence described above (SEQ ID NO:4, 5, 6, 7, or 10) such that it is capable of inducing tissue formation when properly folded and implanted in a mammal. For instance, the synthetic protein can induce bone formation from osteoblasts when implanted in a favorable environment; or it can promote cartilage formation when implanted in an avascular locus or when co-administered with an inhibitor of full bone development.

In another embodiment, the synthetic morphogenic protein used in the method of this invention comprises a sequence sufficiently duplicative of a partial or complete sequence of a COP, e.g., COP5 or COP7. Biosynthetic COP sequences are believed to dimerize during refolding and appear not to be active when reduced. Both homodimeric and heterodimeric COPs are contemplated in this invention. In certain embodiments, this synthetic protein is less than about 200 amino acids long.

These and other synthetic non-native osteogenic proteins may be used in concert with a MPSF and tested using *in vitro*, *ex vivo* or *in vivo* bioassays for progenitor cell induction and tissue regeneration. The proteins in conjunction with the MPSFs of this invention are envisioned to be useful for the repair and regeneration of vascular, bone, cartilage, tendon, ligament, neural and potentially other types of tissue.

Homologous Proteins Having Morphogenic Activity

The morphogenic proteins useful in this invention may be produced by recombinant expression of DNA sequences isolated based on homology with the

osteogenic COP consensus sequences described above. Synthetic COP DNA sequences may be used as probes to retrieve related DNA sequences from a variety of species (see, e.g., Oppermann et al., U.S. Patent Nos. 5,011,591 and 5,258,494, which are incorporated herein by reference).

Morphogenic proteins encoded by a gene that hybridizes with a COP sequence probe are assembled into two subunits disulfide-bonded to produce a heterodimer or homodimer capable of inducing tissue formation when implanted into a mammal. Recombinant BMP-2 and BMP-4 have been shown to have cross-species osteogenic activity as homodimers and as heterodimers assembled with OP-1 subunits.

Morphogenic protein-encoding genes that hybridize to synthetic COP sequence probes include genes encoding Vg1, inhibin, DPP, OP-1, BMP-2 and BMP-4. Vg1 is a known *Xenopus laevis* morphogenic protein involved in early embryonic patterning. Inhibin is another developmental gene that is a member of the BMP family of proteins from *Xenopus laevis*. DPP is an amino acid sequence encoded by a *Drosophila* gene responsible for development of the dorso-ventral pattern. OP-1, BMP-2 and BMP-4 are osteogenic proteins that can induce cartilage, bone and neural tissue formation.

In another embodiment, a morphogenic protein used in the method of this invention may comprise a polypeptide encoded by a nucleic acid that hybridizes under stringent conditions to an "OPS" nucleic acid probe (Oppermann et al., U.S. Patent No. 5,354,557). "OPS" -- standing for OP-1 "short" -- refers to the

portion of the human OP-1 protein defining the conserved 6 cysteine skeleton in the C-terminal active region (97 amino acids; SEQ ID NO:2, residues 335-431).

One example of a stringent hybridization condition is hybridization in 4X SSC at 65°C (or 10°C higher than the calculated melting temperature for a hybrid between the probe and a nucleic acid sequence containing no mis-matched base pairs), followed by washing in 0.1X SSC at the hybridization temperature.

Another stringent hybridization condition is hybridization in 50% formamide, 4X SSC at 42°C.

Thus, in view of this disclosure, the skilled practitioner can readily design and synthesize genes, or isolate genes from cDNA or genomic libraries that encode amino acid sequences having morphogenic activity. These genes can be expressed in prokaryotic or eukaryotic host cells to produce large quantities of active osteogenic or otherwise morphogenic proteins. The recombinant proteins may be in native, truncated, mutant, fusion, or other active forms capable of inducing formation of bone, cartilage, or other types of tissue, as demonstrated by *in vitro* and *ex vivo* bioassays and *in vivo* implantation in mammals, including humans.

Morphogenic Protein Stimulatory Factors (MPSF)

A morphogenic protein stimulatory factor (MPSF) used in the method according to this invention is a factor that is capable of stimulating the ability of a morphogenic protein to induce angiogenesis. In one embodiment, the angiogenesis comprises induction of vascular tissue formation from a progenitor cell. In

another embodiment of this invention, a method for improving the angiogenic activity of a morphogenic protein in a mammal by coadministering an effective amount of a MPSF is provided. The MPSF may have an
5 additive effect on angiogenesis by the morphogenic protein. Preferably, the MPSF has a synergistic effect on angiogenesis by the morphogenic protein.

The progenitor cell that is induced to proliferate and/or differentiate by the morphogenic
10 protein of this invention is preferably a mammalian cell. Preferred progenitor cells include mammalian endothelial cell progenitor cell, all earlier developmental precursors thereof, and all cells that develop therefrom. However, morphogenic proteins are
15 highly conserved throughout evolution, and non-mammalian progenitor cells are also likely to be stimulated by same- or cross-species morphogenic proteins and MPSF combinations. It is thus envisioned that when schemes become available for implanting
20 xenogeneic cells into humans without causing adverse immunological reactions, non-mammalian progenitor cells stimulated by morphogenic protein and a MPSF according to the procedures set forth herein will be useful for tissue regeneration and repair in humans.

25 One or more MPSFs are selected for use in concert with one or more morphogenic proteins according to the desired tissue type to be induced and the site at which the morphogenic protein and MPSF will be administered. The particular choice of a morphogenic
30 protein(s)/MPSF(s) combination and the relative concentrations at which they are combined may be varied systematically to optimize the tissue type induced at a

selected treatment site using the procedures described herein.

The preferred morphogenic protein stimulatory factors (MPSFs) of this invention are selected from the group consisting of hormones, cytokines and growth factors. In one preferred embodiment, MPSFs for inducing angiogenesis in concert with an osteogenic protein comprise at least one compound selected from the group consisting of fibroblast growth factor (FGF), particularly acidic (aFGF) and basic FGF (bFGF), transforming growth factor- β (TGF- β), transforming growth factor- α (TGF- α), epidermal growth factor (EGF), vascular endothelial growth factor (VEGF), endothelial cell growth factor (ECGF), insulin-like growth factor-1 (IGF-1), hepatocyte growth factor (HGF), platelet activating factor (PAF), interleukin-8 (IL-8), placental growth factor (PGF), proliferin, B61, soluble vascular cell adhesion molecule-1 (SVCAM-1), soluble E-selectin, ephrin, 12-hydroxyeicosatetraenoic acid, tat protein of HIV-1, angiogenin, prostaglandin, particularly PGE2 and amino acid variants thereof. More preferred MPSFs for inducing angiogenesis in concert with an osteogenic protein comprise at least one compound selected from the group consisting of basic fibroblast growth factor (bFGF), platelet derived transforming growth factor- β 1 (TGF- β 1) and amino acid variants thereof. One most preferred MPSP is basic fibroblast growth factor (bFGF) and amino acid variants thereof. Another most preferred MPSF is platelet derived transforming growth factor- β 1 (TGF- β) and amino acid variants thereof.

In another preferred embodiment of this invention, the MPSF comprises a compound or an agent that is capable of increasing the bioactivity of another MPSF. Agents that increase MPSF bioactivity include, for example, those that increase the synthesis, half-life, reactivity with other biomolecules such as binding proteins and receptors, or the bioavailability of the MPSF. These agents may comprise hormones, growth factors, peptides, cytokines, carrier molecules such as proteins or lipids, or other factors that increase the expression or the stability of the MPSF.

For example, when the selected MPSF is FGF, agents that increase its bioactivity include heparan sulfate proteoglycans (HSPGs), which may thus function as MPSFs according to this invention.

Preferably, the MPSF is present in an amount capable of synergistically stimulating the tissue inductive activity of the morphogenic protein in a mammal. The relative concentrations of morphogenic protein and MPSF that will optimally induce tissue formation when administered to a mammal may be determined empirically by the skilled practitioner using the procedures described herein.

25 **Testing Putative Morphogenic Protein Stimulatory Factors**

To identify a MPSF that is capable of stimulating the angiogenic activity of a chosen morphogenic protein, an appropriate assay is selected. Initially, it is preferable to perform *in vitro* assays to identify a MPSF that is capable of stimulating the angiogenic activity of a morphogenic protein. A useful

in vitro assay is one which monitors a marker known to correlate with the associated differentiation pathway (see **Examples 1-3**).

Examples 5-6 describe experiments using the osteogenic protein OP-1 to determine its effect on angiogenesis and to identify and optimize an effective concentration of MPSF. OP-1 has some angiogenic activity. Thus, an *in vitro* assay looking at the expression of an angiogenic-associated marker can be used to identify one or more MPSFs that function in concert with OP-1.

Testing Putative MPSFs Using Angiogenesis Assays

A preferred assay for testing potential MPSFs with OP-1 for angiogenic activity is the chorioallantoic membrane (CAM) assay. The CAM assay is a measure of the angiogenic response. The procedure is generally as follows.

First, a MPSF is identified by picking one or more concentrations of a MPSF and testing them alone or in the presence of a morphogenic protein (**Examples 5-6**). Second, the amount of MPSF required to achieve optimal, preferably synergistic, tissue induction in concert with the morphogenic protein is determined by generating dose response curves.

Optionally, one or more additional MPSFs that stimulate or otherwise alter the angiogenic activity induced by a morphogenic protein and a first MPSF may be identified and a new multi-factor dose response curve generated.

Utility of Morphogenic Proteins and MPSFs

The morphogenic proteins alone or in combination with MPSFs of this invention will permit the treatment of a variety of injuries or pathologies where vascular tissue formation is required. The morphogenic proteins alone or in combination can ameliorate or remedy the injuries or pathologies by stimulating angiogenesis.

In one embodiment of this invention, a method for inducing angiogenesis in a mammal by administering an effective amount of a morphogenic protein, with the proviso that said morphogenic protein is not BMP-2 or GDF-5 is provided. In another embodiment of this invention a method for improving the angiogenic inductive activity of a morphogenic protein in a mammal by coadministering with the morphogenic protein an effective amount of a morphogenic protein stimulatory factor is provided.

In one preferred embodiment, the morphogenic protein stimulatory factor has synergistic effects on angiogenesis by the morphogenic protein. In another preferred embodiment the morphogenic protein stimulatory factor has additive effects on angiogenesis by the morphogenic protein.

The morphogenic proteins and MPSFs may be administered at the desired locus in a mammal such that the morphogenic proteins and MPSFs are accessible to the appropriate progenitor cells of the mammal. When a combination of morphogenic protein and MPSF is used to induce angiogenesis, they may be administered either simultaneously or separately to a target locus. For example, there may be the morphogenic protein is

administered first and then the MPSF is administered.
In a preferred embodiment, the target locus is a
vascular tissue defect.

Example 1: Chorioallantoic membrane (CAM) assay

5 Fertile chick eggs (Lowman Brown) were
incubated and prepared for bead implantation on the
third or fourth day of incubation as described (Vu et
al., Lab. Invest., 53, pp. 499-508 (1985); Gould et
al., Life Sci., 56, pp. 587-594 (1995), Kirchner et
10 al., Microvasc. Res., 51, pp. 1-14 (1996)). The
protein pellets were gently placed on the
chorioallantoic membranes (CAMs) on day 10 of
incubation. The eggs were then incubated without
turning until harvest. On day 15 of incubation, i.e.
15 after a total implantation period of 5 days, the CAMs
were fixed in situ with phosphate buffered formalin
(10% solution).

Example 2: Macroscopic Analysis

 Within each treatment group, randomly
20 selected CAMs were photographed using a Wild M400
photomicroscope (Wild Heerbrugg Ltd., Switzerland).
The CAM photomicrographs were evaluated visually in a
masked fashion as previously described (Vu et al.,
supra; Flamme et al., Development, 111, pp. 683-690
25 (1991); Olivo et al., Anat. Rec., 234, pp. 105-115
(1992)) with minor modifications. The results were
described as: (i) no response: blood vessels
undisturbed around the beads and surrounding CAM, (ii)
questionable response: blood vessels radiating from the
30 surrounding CAM and directionally shifting towards the

beads in a spoke-wheel-like pattern or (iii) positive response: blood vessels converging on the area around the beads in a prominent spoke-wheel pattern.

Example 3: Microscopic Analysis

5 The pellets and the adjacent tissue of the
CAMs were surgically excised, placed in formalin,
dehydrated through ethanol and embedded in paraffin wax
as described (Yang and Moses, J. Cell. Biol., 111, pp.
731-341 (1990)). Serial sections of the tissues were
10 cut at 5 μ m, mounted on glass slides and stained using
a modified Goldner's trichrome technique (Ripamonti et
al., Matrix, 12, pp. 369-380 (1992); (Ripamonti et al.,
Bone Morphogenetic Proteins: Biology, Biochemistry and
Reconstructive Surgery, Lindholm T.S. ed., pp. 131-145
15 (1996); Bradbury and Rae, Bone, In: Theory and Practice
of Histological Techniques, Bancroft and Stevens, eds.,
pp. 113-138 (1996); Page et al., Bone, In: Theory and
Practice of Histological Techniques, Bancroft and
Stevens, eds., pp. 309-340 (1996)). The stain colors
20 nuclei blue-black, erythrocytes red, cytoplasm red-
purple, fibrin red and collagen blue. The sections
were examined by light microscopy and photographed
using a Provis AX70 research microscope (Olympus
Optical Co., Japan). Representative histologic
25 sections were evaluated microscopically with the
support of computer software (flexible Image Analysis
System® ver. 2.15, CSIR, South Africa) installed in
Pentium computer with a color monitor.

 The mean CAM thickness (μ m) was measured as
30 previously described (Yang and Moses, *supra*) with minor
modification. Briefly, the width of the entire CAM

(ecto-, meso- and endoderm jointly) was measured across the central region below the implanted beads and across the peripheral regions distant from the beads using an individual distance array of 5 regularly spaced
5 sampling points. The point intervals were determined with the aid of a superimposed lattice grid (Zeiss Integration Platte II) in order to diminish user-bias. In each representative sample section, the thickness ratio (average thickness of the centrally located
10 regions/average thickness of the peripheral non-reactive regions) was computed. These relative changes in membrane thickness were coupled with the changes in the number, size or density of blood vessels and fibrous tissues in the regions, used for the overall
15 evaluation of the angiogenic responses of the various CAMs.

Based on this qualitative evaluation, the different treatment groups were ranked as (I) weak (negligible or no increase in CAM thickness with
20 limited or no increase in capillaries and fibrous tissues), (ii) moderate (moderate increase in CAM thickness with a moderate increase in capillaries and fibrous tissue), (iii) intense (moderate increase in CAM thickness with extensive increase in capillaries
25 and fibrous tissue) or (iv) very intense (extensive increase in CAM thickness with extensive increase in capillaries and fibrous tissue). The experiments were performed in quadruplicate and repeated at least three times.

Example 4: Statistical Analysis

Quantifiable data (macroscopic evaluation and thickness ratios) were, respectively, analyzed by Two-way or One-way analysis of variance (ANOVA) using
5 GraphPad Prism™ version 2 (San Diego, USA). Results at $p < 0.05$ were considered significant.

Example 5: Synergistic Effect of bFGF and TGF- β on OP-1 Induced Angiogenesis - Macroscopic Analysis

10 **Figures 1 and 9** show that the single application of the morphogens pTGF- β 1 (20 ng), bFGF (500 ng) or hOP-1 (100 and 1000 ng) and the binary application of hOP-1/bFGF (100/100 ng) or hOP-1/pTGF- β 1 (100/5 and 100/20 ng) on the chick chorioallantoic membrane (CAM)
15 demonstrated significantly higher positive angiogenic scores ($\geq 50.0\%$) compared to the BSA (500 ng) controls (12.5%). The hOP-1/bFGF and hOP-1/pTGF- β 1 combinations elicited the highest number of positive responses ($\geq 75\%$). The highest number of questionable angiogenic
20 responses (37.5%) was produced by the lower dose of hOP-1 (100 ng). The morphogens also exhibited lower non-responsive angiogenic scores ($\leq 25\%$) compared to the controls (62.5%); with the hOP-1/pTGF- β 1 combinations eliciting the loses number of non-responsive scores
25 (0%).

**Example 6: Synergistic Effect of bFGF and TGF- β on
OP-1 Induced Angiogenesis - Microscopic
Analysis**

A. CAM Thickness

5 **Figures 2-8**, show that the regions of the CAM
in the proximity of the beads soaked in the pTGF- β 1 (20
ng), bFGF (500 ng) and hOP-1 (100 and 1000 ng)
exhibited a significant increase in the thickness of
the CAM compared to the BSA (500 ng) controls. In
10 addition, the binary combination of hOP-1/bFGF
(100/100 ng) and hOP-1/pTGF- β 1 (100/5 and 100/20 ng)
elicited a significantly higher increase in the CAM
thickness than the single application of the respective
morphogens. the hOP-1/pTGF- β 1 combinations elicited
15 the highest increase in membrane thickness. All the
increases in the thickness of the reactive CAMS were
accompanied by significant changes in the cell
morphology, including an increase in the number and
size of blood vessels with nucleated erythrocytes and
20 an increase in fibrous tissue density (fibroplasia).

B. Overall Angiogenic Score

Control: beads soaked with 500 ng BSA
resulted in a negligible change in the overall
thickness of the CAM (**Figure 2**) and a weak or
25 negligible overall angiogenic reaction in the CAM
(**Figure 10**). As shown in **Figure 3**, the ectoderm,
mesoderm and endoderm of the CAM beneath the beads
developed in a virtually normal pattern when compared
to the adjacent non-exposed CAM. The ectoderm and
30 endoderm were flat, single-layered or simple epithelia
in the entire expanse of the CAM. The ectoderm, showed
normal development of the intradermal capillaries. The

mesoderm showed mainly sparsely arranged fibrous tissue with scattered blood vessels with nucleated erythrocytes localized centrally and also adjacent to the ectoderm. The mesoderm adjacent to the endoderm
5 was deficient of blood vessels.

pTGF- β 1: The application of 20 ng pTGF- β 1 resulted in a moderate increase in the thickness of the reactive CAM (**Figure 2**) and a moderate overall angiogenic response (**Figure 10**). **Figure 4** shows that
10 the reaction center was primarily located in the region of the mesoderm adjacent to the endoderm. There was very marked expansion or thickening of the mesoderm and very intense stratification of the endoderm, with signs of shedding of the outermost cell layers of the
15 stratified epithelium. The mesoderm was also characterized by a widespread increase in the number of capillary blood vessels, as well as increases in the density of the mesenchymal stroma through a condensation of fibroblasts and connective tissue
20 fibers, including blue-staining collagen fibers, adjacent to the endoderm. The ectoderm, in some sections, was altered into a bilayered squamous epithelium.

bFGF: The application of 500 ng bFGF resulted
25 in a moderate increase in the thickness of the reactive CAM (**Figure 2**) and an intense overall angiogenic response (**Figure 10**). The histological features of the reaction show that the response was characterized by intense stratification of both ectoderm and endoderm
30 (**Figure 5**). The expanded mesoderm was characterized by augmentation of large capillary blood vessels and an

increase in the density of new capillaries and fibrous tissue most primarily in the regions adjacent to both the ectoderm and the endoderm. Blue staining collagen fibers were distributed widely in the reactive mesoderm. Clusters of cells, with a similar morphological appearance to and, presumably, contiguous with the stratified ectoderm were observed in the mesoderm.

hOP-1: The application of 100 ng and 1000 ng of hOP-1 resulted in a dose-dependent moderate to high increases in the thickness of the reactive CAM (**Figure 2**) and moderate to intense overall angiogenic responses, respectively (**Figure 10**). The reaction of the CAM to 100 ng hOP-1 (**Figure 6A**) was primarily localized at the region of the mesoderm subadjacent to the ectoderm. There was intense stratification of the ectoderm and a weak growth of the endoderm. The mesoderm was expanded, with numerous capillaries and diffuse fibrous tissue distributed mainly in the region near the ectoderm. The reaction to 1000 ng of hOP-1 (**Figure 6B**) was also mainly confined to the region of the mesoderm subadjacent to the ectoderm but was more intense than the response elicited by 100 ng of hOP-1. There was very intense stratification of the ectoderm and a moderate cellular expansion of the endoderm. The mesoderm was enlarged, with new capillaries and very dense fibrous tissue distributed mainly in the region subadjacent to the ectoderm. The previously intraectodermal capillaries were located underneath the blood vessel-free stratified ectoderm. In the mesoderm, hydropic cells and necrotic cells were

observed in a few groups of cells displaying a morphological appearance identical to the cells of the stratified ectoderm. With both doses of hOP-1 (**Figures 6A and 6B**) there were multiple distended blood vessels with nucleated erythrocytes in the mesoderm.

hOP-1/bFGF: The binary application of 100 ng hOP-1 with 100 ng bFGF resulted in a moderate to high increase in the thickness of the reactive CAM (**Figure 2**) and a very intense angiogenic response (**Figure 10**). The combination resulted in intense alteration of the ectoderm, mesoderm, and endoderm (**Figure 7**). The ectodermal epithelium was thickened via stratification and the endodermal cells acquired a columnar shape in addition to cellular hypertrophy. The mesoderm was more consolidated, exhibiting an increased density of fibroblasts and small blood vessels which were widely distributed throughout the reactive region of the CAM. The fibrous tissue, comprising mainly blue-staining collagen, was very dense and spread throughout the perimeter of the reactive mesoderm.

hOP-1/pTGF- β 1: The binary application of 100 ng hOP-1 with pTGF- β 1 (5 and 20 ng) exhibited a very high increase in the thickness of the reactive CAM (**Figure 2**) and a very intense overall angiogenic response (**Figure 10**). The increase in the CAM thickness was highest among all the applied morphogenic proteins and MPSFs. All the three layers of the CAM were characterized by very intense hyperplasia (**Figures 8A and 8B**). The responses resulting from both applications were characterized by a high condensation of mesenchyme and fibrous tissue accompanying and

extensive proliferation of large and small blood
vessels. There was also the presence of dead cells in
the mesoderm that were located within groups of cells
morphologically identical to the cells of the
5 stratified ectoderm. A concomitant envelopment of the
gel beads by the CAM tissue was frequently evident
(Figure 8B).

While we have described a number of
embodiments of this invention, it is apparent that our
10 basic constructions may be altered to provide other
embodiments which utilize the methods of this
invention. Therefore, it will be appreciated that the
scope of this invention is to be defined by the
appended claims, rather than by the specific
15 embodiments which have been presented by way of
example.

What is claimed:

1. A method for inducing angiogenesis in a mammal by administering an effective amount of a morphogenic protein; with the proviso that said morphogenic protein is not BMP-2 or GDF-5.
2. A method for improving the angiogenic inductive activity of a morphogenic protein in a mammal by coadministering with the morphogenic protein an effective amount of a morphogenic protein stimulatory factor.
3. The method according to claim 2, wherein the morphogenic protein stimulatory factor has additive effects on angiogenesis by the morphogenic protein.
4. The method according to claim 2, wherein the morphogenic protein stimulatory factor has synergistic effects on angiogenesis by the morphogenic protein.
5. The method according to any one of claims 1 to 4, wherein the morphogenic protein is an osteogenic protein that is capable of inducing angiogenesis.
6. The method according to any one of claims 1 to 4, wherein the morphogenic protein comprises an amino acid sequence selected from the group consisting of BMP-3, BMP-4, BMP-5, BMP-6, OP-1 (BMP-7), BMP-8, BMP-9, BMP-10, BMP-11, BMP-12, BMP-13, BMP-14, BMP-15, COP-5, COP-7 and an amino acid sequence variant thereof.

7. The method according to any one of claims 1 to 4, wherein the morphogenic protein is a monomeric species.

8. The method according to claim 7, wherein the monomeric species is selected from the group consisting
5 of OP-1, BMP-5, BMP-6, BMP-8, GDF-6, GDF-7 and amino acid sequence variants thereof.

9. The method according to any one of claims 1 to 4, wherein the morphogenic protein comprises a disulfide bonded dimeric species.

10 10. The method according to claim 9, wherein the dimeric species comprises a polypeptide selected from the group consisting of OP-1, BMP-5, BMP-6, BMP-8, GDF-6, GDF-7 and amino acid sequence variants thereof.

11. The method according to any one of claims 1 to 4,
15 wherein the morphogenic protein is OP-1.

12. The method according to any one of claims 1 to 4, wherein the morphogenic protein is produced by the expression of a recombinant DNA molecule in a host cell.

20 13. The method according to any one of claims 2 to 4, wherein the morphogenic protein stimulatory factor comprises at least one compound selected from the group consisting acidic fibroblast growth factor (aFGF), basic fibroblast growth factor FGF (bFGF), transforming
25 growth factor- β (TGF- β), transforming growth factor- α (TGF- α), epidermal growth factor (EGF), vascular

007660" 9940456 033100

endothelial growth factor (VEGF), endothelial cell growth factor (ECGF), insulin-like growth factor-1 (IGF-1), hepatocyte growth factor (HGF), platelet activating factor (PAF), interleukin-8 (IL-8),

5 placental growth factor (PGF), proliferin, B61, soluble vascular cell adhesion molecule-1 (SVCAM-1), soluble E-selectin, ephrin, 12-hydroxyeicosatetraenoic acid, tat protein of HIV-1, angiogenin, prostaglandin and amino acid sequence variants thereof.

10 14. The method according to any one of claims 2 to 4, wherein the morphogenic protein stimulatory factor comprises at least one compound selected from the group consisting of basic fibroblast growth factor (bFGF), platelet derived transforming growth factor- β 1 (TGF- β 1)
15 and amino acid sequence variants thereof.

15. The method according to any one of claims 2 to 4, wherein the morphogenic protein stimulatory factor is selected from the group consisting of basic fibroblast growth factor (bFGF) and amino acid sequence variants
20 thereof.

16. The method according to any one of claims 2 to 4, wherein the morphogenic protein stimulatory factor is selected from the group consisting of platelet derived transforming growth factor- β 1 (TGF- β 1) and amino acid
25 sequence variants thereof.

17. The method according to any one of claims 2 to 4, wherein the morphogenic protein and the morphogenic

protein stimulatory factor are administered
simultaneously to a target locus.

18. The method according to any one of claims 2 to 4,
wherein the morphogenic protein and the morphogenic
5 protein stimulatory factor are administered separately
to a target locus.

19. The method according to claim 17, wherein the
target locus is a vascular tissue defect.

20. The method according to claim 18, wherein the
10 target locus is a vascular tissue defect.

ABSTRACT

The present invention provides a method for inducing angiogenesis at a target locus in a mammal using morphogenic proteins. In addition, this
5 invention also features a method for improving the angiogenic capability of a morphogenic protein at a target locus in a mammal. In this method, the morphogenic protein is capable of inducing angiogenesis when accessible to a progenitor cell in the mammal, and
10 the morphogenic protein stimulatory factor enhances that capability. The morphogenic protein and morphogenic protein stimulatory factor can be administered simultaneously to the target locus. Alternatively, the two components are administered
15 separately, in any order.

007620" 9940450

Fig. 1






Fig. 2



09540465, 033100




Fig. 3




Fig. 4

007E0" 99404560






Fig. 5



007EEO" 99404550






Fig. 7



[illegible][illegible]

Fig. 10

	CAM Angiogenic Response							
	BSA (500 ng)	TGF- β 1 (20 ng)	bFGF (500 ng)	OP-1 (100 ng)	OP-1 (1000 ng)	OP-1 (100 ng) + bFGF (100 ng)	OP-1 (100 ng) + TGF- β 1 (5 ng)	OP-1 (100 ng) + TGF- β 1 (20 ng)
Grade								
Very Intense						X	X	X
Intense			X		X			
Moderate		X		X				
Weak	X							

00T.E.E.0" 93404560

**DECLARATION AND POWER OF ATTORNEY
FOR PATENT APPLICATION**

As a below named inventor, I hereby declare that:

My residence, post office address and citizenship are as stated below next to my name;

I believe I am the original, first and sole inventor (if only one name is listed below) or an original, first and joint inventor (if plural names are listed below) of the subject matter which is claimed and for which a patent is sought on the invention entitled:

METHODS AND COMPOSITIONS FOR IDENTIFYING
MORPHOGENIC PROTEIN ANALOGS USING MORPHOGENIC
PROTEIN RESPONSIVE INHIBITORY ELEMENTS

the specification of which

(check [X] is attached hereto
one)

[] was filed on _____ as
Application Serial No. _____
and was amended on _____.
(if applicable)

I hereby state that I have reviewed and understand the contents of the above-identified specification, including the claims, as amended by any amendment referred to above.

I do not know and do not believe that the invention was ever patented or described in any printed publication in any country before my or our invention thereof or more than one year prior to this application.

I do not know and do not believe that the invention was in public use or on sale in the United States of America more than one year prior to this application.

I acknowledge the duty to disclose to the United States Patent and Trademark Office all information known by me to be material to patentability as defined in Title 37, Code of Federal Regulations, § 1.56.

I hereby claim foreign priority benefits under Title 35, United States Code, § 119 of any foreign application(s) for

patent or inventor's certificate listed below and have also identified below any foreign application for patent or inventor's certificate having a filing date before that of the application on which priority is claimed:

Prior Foreign Application(s)

			<u>Priority Claimed</u>	
			[]	[]
<u>(Number)</u>	<u>(Country)</u>	<u>(Day/Month/Year Filed)</u>	Yes	No
<u>(Number)</u>	<u>(Country)</u>	<u>(Day/Month/Year Filed)</u>	[]	[]
			Yes	No

I hereby claim the benefit under Title 35, United States Code, § 120 of any United States application(s) listed below and, insofar as the subject matter of each of the claims of this application is not disclosed in the prior United States application in the manner provided by the first paragraph of Title 35, United States Code, § 112, I acknowledge the duty to disclose to the United States Patent and Trademark Office all information known by me to be material to patentability as defined in Title 37, Code of Federal Regulations, § 1.56 which became available between the filing date of the prior application and the national or PCT international filing date of this application:

<u>(Application Serial No.)</u>	<u>(Filing Date)</u>	<u>(Status) (patented, pending, abandoned)</u>
<u>(Application Serial No.)</u>	<u>(Filing Date)</u>	<u>(Status) (patented, pending, abandoned)</u>

As a named inventor, I hereby appoint the following attorneys or agents to prosecute this application and transact all business in the United States Patent and Trademark Office connected therewith:

James F. Haley, Jr., (Reg. No. 27,794)

Karen Mangasarian, (Reg. No. 43,772)

007660" 99404560

Send correspondence to: James F. Haley, Jr.
FISH & NEAVE
1251 Avenue of the Americas
New York, New York 10020-1104

Direct telephone calls to: James F. Haley, Jr.
(212) 596-9000

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

Full name of first inventor Ugo Ripamonti

First Inventor's signature _____ Date _____

Residence 21 The Regency, 167 Daisy Street, Strathavon,
Sandton 2196, South Africa

Citizenship Italy/South Africa (naturalized)

Post Office Address 21 The Regency, 167 Daisy Street,
Strathavon, Sandton 2196, South Africa

Full name of second joint inventor Lentsha Nathaniel Ramoshebi

Second Inventor's signature _____ Date _____

Residence 456 A Mkonza Street, White City Jabavu, PO Pimville
Johannesburg 1809, South Africa

Citizenship South Africa

Post Office Address 456 A Mkonza Street, White City Jabavu,
PO Pimville, Johannesburg 1809, South Africa

SEQUENCE LISTING

<110> RIPAMONTI, UGO
RAMOSHEBI, LENTSHA N.

<120> METHODS FOR INDUCING ANGIOGENESIS USING MORPHOGENIC
PROTEINS AND STIMULATORY FACTORS

<130> STK-6

<140>

<141>

<160> 10

<170> PatentIn Ver. 2.1

<210> 1

<211> 1822

<212> DNA

<213> Homo sapiens

<220>

<221> CDS

<222> (49)..(1341)

<400> 1

```

ggtgcgggcc cggagcccgg agcccgggta gcgcgtagag ccggcgcg atg cac gtg   57
                                     Met His Val
                                     1

cgc tca ctg cga gct gcg gcg ccg cac agc ttc gtg gcg ctc tgg gca   105
Arg Ser Leu Arg Ala Ala Ala Pro His Ser Phe Val Ala Leu Trp Ala
   5                      10                      15

ccc ctg ttc ctg ctg cgc tcc gcc ctg gcc gac ttc agc ctg gac aac   153
Pro Leu Phe Leu Leu Arg Ser Ala Leu Ala Asp Phe Ser Leu Asp Asn
  20                      25                      30                      35

gag gtg cac tcg agc ttc atc cac cgg cgc ctc cgc agc cag gag cgg   201
Glu Val His Ser Ser Phe Ile His Arg Arg Leu Arg Ser Gln Glu Arg
                40                      45                      50

cgg gag atg cag cgc gag atc ctc tcc att ttg ggc ttg ccc cac cgc   249
Arg Glu Met Gln Arg Glu Ile Leu Ser Ile Leu Gly Leu Pro His Arg
   55                      60                      65

ccg cgc ccg cac ctc cag ggc aag cac aac tcg gca ccc atg ttc atg   297
Pro Arg Pro His Leu Gln Gly Lys His Asn Ser Ala Pro Met Phe Met
   70                      75                      80

ctg gac ctg tac aac gcc atg gcg gtg gag gag ggc ggc ggg ccc ggc   345
Leu Asp Leu Tyr Asn Ala Met Ala Val Glu Glu Gly Gly Gly Pro Gly
   85                      90                      95

ggc cag ggc ttc tcc tac ccc tac aag gcc gtc ttc agt acc cag ggc   393
Gly Gln Gly Phe Ser Tyr Pro Tyr Lys Ala Val Phe Ser Thr Gln Gly
  100                      105                      110                      115

```

ccc cct ctg gcc agc ctg caa gat agc cat ttc ctc acc gac gcc gac	441
Pro Pro Leu Ala Ser Leu Gln Asp Ser His Phe Leu Thr Asp Ala Asp	
120 125 130	
atg gtc atg agc ttc gtc aac ctc gtg gaa cat gac aag gaa ttc ttc	489
Met Val Met Ser Phe Val Asn Leu Val Glu His Asp Lys Glu Phe Phe	
135 140 145	
cac cca cgc tac cac cat cga gag ttc cgg ttt gat ctt tcc aag atc	537
His Pro Arg Tyr His His Arg Glu Phe Arg Phe Asp Leu Ser Lys Ile	
150 155 160	
cca gaa ggg gaa gct gtc acg gca gcc gaa ttc cgg atc tac aag gac	585
Pro Glu Gly Glu Ala Val Thr Ala Ala Glu Phe Arg Ile Tyr Lys Asp	
165 170 175	
tac atc cgg gaa cgc ttc gac aat gag acg ttc cgg atc agc gtt tat	633
Tyr Ile Arg Glu Arg Phe Asp Asn Glu Thr Phe Arg Ile Ser Val Tyr	
180 185 190 195	
cag gtg ctc cag gag cac ttg ggc agg gaa tgc gat ctc ttc ctg ctc	681
Gln Val Leu Gln Glu His Leu Gly Arg Glu Ser Asp Leu Phe Leu Leu	
200 205 210	
gac agc cgt acc ctc tgg gcc tgc gag gag ggc tgg ctg gtg ttt gac	729
Asp Ser Arg Thr Leu Trp Ala Ser Glu Glu Gly Trp Leu Val Phe Asp	
215 220 225	
atc aca gcc acc agc aac cac tgg gtg gtc aat ccg cgg cac aac ctg	777
Ile Thr Ala Thr Ser Asn His Trp Val Val Asn Pro Arg His Asn Leu	
230 235 240	
ggc ctg cag ctc tgc gtg gag acg ctg gat ggg cag agc atc aac ccc	825
Gly Leu Gln Leu Ser Val Glu Thr Leu Asp Gly Gln Ser Ile Asn Pro	
245 250 255	
aag ttg gcg ggc ctg att ggg cgg cac ggg ccc cag aac aag cag ccc	873
Lys Leu Ala Gly Leu Ile Gly Arg His Gly Pro Gln Asn Lys Gln Pro	
260 265 270 275	
ttc atg gtg gct ttc ttc aag gcc acg gag gtc cac ttc cgc agc atc	921
Phe Met Val Ala Phe Phe Lys Ala Thr Glu Val His Phe Arg Ser Ile	
280 285 290	
cgg tcc acg ggg agc aaa cag cgc agc cag aac cgc tcc aag acg ccc	969
Arg Ser Thr Gly Ser Lys Gln Arg Ser Gln Asn Arg Ser Lys Thr Pro	
295 300 305	
aag aac cag gaa gcc ctg cgg atg gcc aac gtg gca gag aac agc agc	1017
Lys Asn Gln Glu Ala Leu Arg Met Ala Asn Val Ala Glu Asn Ser Ser	
310 315 320	
agc gac cag agg cag gcc tgt aag aag cac gag ctg tat gtc agc ttc	1065
Ser Asp Gln Arg Gln Ala Cys Lys Lys His Glu Leu Tyr Val Ser Phe	
325 330 335	

cga gac ctg ggc tgg cag gac tgg atc atc gcg cct gaa ggc tac gcc	1113
Arg Asp Leu Gly Trp Gln Asp Trp Ile Ile Ala Pro Glu Gly Tyr Ala	
340 345 350 355	
gcc tac tac tgt gag ggg gag tgt gcc ttc cct ctg aac tcc tac atg	1161
Ala Tyr Tyr Cys Glu Gly Glu Cys Ala Phe Pro Leu Asn Ser Tyr Met	
360 365 370	
aac gcc acc aac cac gcc atc gtg cag acg ctg gtc cac ttc atc aac	1209
Asn Ala Thr Asn His Ala Ile Val Gln Thr Leu Val His Phe Ile Asn	
375 380 385	
ccg gaa acg gtg ccc aag ccc tgc tgt gcg ccc acg cag ctc aat gcc	1257
Pro Glu Thr Val Pro Lys Pro Cys Cys Ala Pro Thr Gln Leu Asn Ala	
390 395 400	
atc tcc gtc ctc tac ttc gat gac agc tcc aac gtc atc ctg aag aaa	1305
Ile Ser Val Leu Tyr Phe Asp Asp Ser Ser Asn Val Ile Leu Lys Lys	
405 410 415	
tac aga aac atg gtg gtc cgg gcc tgt ggc tgc cac tagctcctcc	1351
Tyr Arg Asn Met Val Val Arg Ala Cys Gly Cys His	
420 425 430	
gagaattcag accctttggg gccaaagtttt tctggatcct ccattgctcg ccttggccag	1411
gaaccagcag accaactgcc ttttgtgaga ccttccccctc cctatcccca acttttaaagg	1471
tgtgagagta ttaggaaaca tgagcagcat atggctttttg atcagttttt cagtggcagc	1531
atccaatgaa caagatccta caagctgtgc aggcaaaacc tagcaggaaa aaaaaacaac	1591
gcataaagaa aaatggccgg gccaggtcat tggctgggaa gtctcagcca tgcacggact	1651
cgttttccaga ggtaattatg agcgccctacc agccaggcca ccagccgtg ggaggaaggg	1711
ggcgtggcaa ggggtgggca cattggtgtc tgtgcgaaag gaaaattgac ccggaagttc	1771
ctgtaataaa tgtcacaata aaacgaatga atgaaaaaaaa aaaaaaaaaa a	1822
<210> 2	
<211> 431	
<212> PRT	
<213> Homo sapiens	
<400> 2	
Met His Val Arg Ser Leu Arg Ala Ala Ala Pro His Ser Phe Val Ala	
1 5 10 15	
Leu Trp Ala Pro Leu Phe Leu Leu Arg Ser Ala Leu Ala Asp Phe Ser	
20 25 30	
Leu Asp Asn Glu Val His Ser Ser Phe Ile His Arg Arg Leu Arg Ser	
35 40 45	
Gln Glu Arg Arg Glu Met Gln Arg Glu Ile Leu Ser Ile Leu Gly Leu	
50 55 60	

Pro 65	His	Arg	Pro	Arg	Pro 70	His	Leu	Gln	Gly	Lys 75	His	Asn	Ser	Ala	Pro 80
Met	Phe	Met	Leu	Asp 85	Leu	Tyr	Asn	Ala	Met 90	Ala	Val	Glu	Glu	Gly 95	Gly
Gly	Pro	Gly	Gly 100	Gln	Gly	Phe	Ser	Tyr 105	Pro	Tyr	Lys	Ala	Val 110	Phe	Ser
Thr	Gln	Gly 115	Pro	Pro	Leu	Ala	Ser 120	Leu	Gln	Asp	Ser	His 125	Phe	Leu	Thr
Asp	Ala 130	Asp	Met	Val	Met	Ser 135	Phe	Val	Asn	Leu	Val 140	Glu	His	Asp	Lys
Glu 145	Phe	Phe	His	Pro	Arg 150	Tyr	His	His	Arg	Glu 155	Phe	Arg	Phe	Asp	Leu 160
Ser	Lys	Ile	Pro	Glu 165	Gly	Glu	Ala	Val	Thr 170	Ala	Ala	Glu	Phe	Arg 175	Ile
Tyr	Lys	Asp	Tyr 180	Ile	Arg	Glu	Arg	Phe 185	Asp	Asn	Glu	Thr	Phe 190	Arg	Ile
Ser	Val 195	Tyr	Gln	Val	Leu	Gln	Glu 200	His	Leu	Gly	Arg	Glu 205	Ser	Asp	Leu
Phe 210	Leu	Leu	Asp	Ser	Arg	Thr 215	Leu	Trp	Ala	Ser	Glu 220	Glu	Gly	Trp	Leu
Val 225	Phe	Asp	Ile	Thr	Ala 230	Thr	Ser	Asn	His	Trp 235	Val	Val	Asn	Pro	Arg 240
His	Asn	Leu	Gly 245	Leu	Gln	Leu	Ser	Val	Glu 250	Thr	Leu	Asp	Gly	Gln 255	Ser
Ile	Asn	Pro	Lys 260	Leu	Ala	Gly	Leu	Ile 265	Gly	Arg	His	Gly	Pro	Gln	Asn
Lys	Gln	Pro	Phe 275	Met	Val	Ala	Phe 280	Phe	Lys	Ala	Thr	Glu 285	Val	His	Phe
Arg 290	Ser	Ile	Arg	Ser	Thr	Gly 295	Ser	Lys	Gln	Arg	Ser 300	Gln	Asn	Arg	Ser
Lys 305	Thr	Pro	Lys	Asn	Gln 310	Glu	Ala	Leu	Arg	Met 315	Ala	Asn	Val	Ala	Glu 320
Asn	Ser	Ser	Ser	Asp 325	Gln	Arg	Gln	Ala	Cys 330	Lys	Lys	His	Glu	Leu 335	Tyr
Val	Ser	Phe	Arg 340	Asp	Leu	Gly	Trp	Gln 345	Asp	Trp	Ile	Ile	Ala 350	Pro	Glu
Gly	Tyr	Ala 355	Ala	Tyr	Tyr	Cys	Glu 360	Gly	Glu	Cys	Ala	Phe 365	Pro	Leu	Asn

Ser Tyr Met Asn Ala Thr Asn His Ala Ile Val Gln Thr Leu Val His
370 375 380

Phe Ile Asn Pro Glu Thr Val Pro Lys Pro Cys Cys Ala Pro Thr Gln
385 390 395 400

Leu Asn Ala Ile Ser Val Leu Tyr Phe Asp Asp Ser Ser Asn Val Ile
405 410 415

Leu Lys Lys Tyr Arg Asn Met Val Val Arg Ala Cys Gly Cys His
420 425 430

<210> 3

<211> 102

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: OPX

<220>

<223> each Xaa is independently selected from a group of
one or more specified amino acids as defined in
the specification

<400> 3

Cys Xaa Xaa His Glu Leu Tyr Val Ser Phe Xaa Asp Leu Gly Trp Xaa
1 5 10 15

Asp Trp Xaa Ile Ala Pro Xaa Gly Tyr Xaa Ala Tyr Tyr Cys Glu Gly
20 25 30

Glu Cys Xaa Phe Pro Leu Xaa Ser Xaa Met Asn Ala Thr Asn His Ala
35 40 45

Ile Xaa Gln Xaa Leu Val His Xaa Xaa Xaa Pro Xaa Xaa Val Pro Lys
50 55 60

Xaa Cys Cys Ala Pro Thr Xaa Leu Xaa Ala Xaa Ser Val Leu Tyr Xaa
65 70 75 80

Asp Xaa Ser Xaa Asn Val Ile Leu Xaa Lys Xaa Arg Asn Met Val Val
85 90 95

Xaa Ala Cys Gly Cys His
100

<210> 4

<211> 97

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Generic-Seq-7

<220>

00540466 03300

<223> each Xaa is independently selected from a group of one or more specified amino acids as defined in the specification

<400> 4

Leu Xaa Xaa Xaa Phe Xaa Xaa Xaa Gly Trp Xaa Xaa Xaa Xaa Xaa Xaa
1 5 10 15

Pro Xaa Xaa Xaa Xaa Ala Xaa Tyr Cys Xaa Gly Xaa Cys Xaa Xaa Pro
20 25 30

Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Asn His Ala Xaa Xaa Xaa Xaa Xaa
35 40 45

Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Cys Cys Xaa Pro
50 55 60

Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Leu Xaa Xaa Xaa Xaa Xaa Xaa Xaa
65 70 75 80

Val Xaa Leu Xaa Xaa Xaa Xaa Xaa Met Xaa Val Xaa Xaa Cys Xaa Cys
85 90 95

Xaa

<210> 5

<211> 102

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Generic-Seq-8

<220>

<223> each Xaa is independently selected from a group of one or more specified amino acids as defined in the specification

<400> 5

Cys Xaa Xaa Xaa Xaa Leu Xaa Xaa Xaa Phe Xaa Xaa Xaa Gly Trp Xaa
1 5 10 15

Xaa Xaa Xaa Xaa Xaa Pro Xaa Xaa Xaa Xaa Ala Xaa Tyr Cys Xaa Gly
20 25 30

Xaa Cys Xaa Xaa Pro Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Asn His Ala
35 40 45

Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa
50 55 60

Xaa Cys Cys Xaa Pro Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Leu Xaa Xaa
65 70 75 80

Xaa Xaa Xaa Xaa Xaa Val Xaa Leu Xaa Xaa Xaa Xaa Xaa Met Xaa Val
85 90 95

DATE 09-10-2000


```

<210> 8
<211> 5
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Generic Sequence

<220>
<223> each Xaa is independently selected from a group of
      one or more specified amino acids as defined in
      the specification

<400> 8
Cys Xaa Xaa Xaa Xaa
  1                               5

<210> 9
<211> 5
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Generic Sequence

<220>
<223> each Xaa is independently selected from a group of
      one or more specified amino acids as defined in
      the specification

<400> 9
Cys Xaa Xaa Xaa Xaa
  1                               5

<210> 10
<211> 102
<212> PRT

```

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Generic Sequence

<220>

<223> each Xaa represents any amino acid residue

<400> 10

Cys Xaa Xaa Xaa Xaa Leu Xaa Val Xaa Phe Xaa Asp Xaa Glu Trp Xaa
1 5 10 15

Xaa Trp Xaa Xaa Xaa Pro Xaa Gly Xaa Xaa Ala Xaa Tyr Cys Xaa Gly
20 25 30

Xaa Cys Xaa Xaa Pro Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Asn His Ala
35 40 45

Xaa Xaa Gln Xaa Xaa Val Xaa Xaa Xaa Asn Xaa Xaa Xaa Xaa Pro Xaa
50 55 60

Xaa Cys Cys Xaa Pro Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Leu Xaa Xaa
65 70 75 80

Xaa Xaa Xaa Xaa Xaa Val Xaa Leu Xaa Xaa Tyr Xaa Xaa Met Xaa Val
85 90 95

Xaa Xaa Cys Xaa Cys Xaa
100

001620-0940450